Ignite Creation Date:
2025-12-25 @ 2:14 AM
Ignite Modification Date:
2026-03-07 @ 10:18 PM
Study NCT ID:
NCT03941860
Status:
COMPLETED
Last Update Posted:
2025-05-23
First Post:
2019-05-07
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Testing the Addition of Ixazomib/Placebo to Lenalidomide in Patients With Evidence of Residual Multiple Myeloma, OPTIMUM Trial
Sponsor:
Organization:
Raw JSON
{'hasResults': True, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D009101', 'term': 'Multiple Myeloma'}], 'ancestors': [{'id': 'D054219', 'term': 'Neoplasms, Plasma Cell'}, {'id': 'D009370', 'term': 'Neoplasms by Histologic Type'}, {'id': 'D009369', 'term': 'Neoplasms'}, {'id': 'D020141', 'term': 'Hemostatic Disorders'}, {'id': 'D014652', 'term': 'Vascular Diseases'}, {'id': 'D002318', 'term': 'Cardiovascular Diseases'}, {'id': 'D010265', 'term': 'Paraproteinemias'}, {'id': 'D001796', 'term': 'Blood Protein Disorders'}, {'id': 'D006402', 'term': 'Hematologic Diseases'}, {'id': 'D006425', 'term': 'Hemic and Lymphatic Diseases'}, {'id': 'D006474', 'term': 'Hemorrhagic Disorders'}, {'id': 'D008232', 'term': 'Lymphoproliferative Disorders'}, {'id': 'D007160', 'term': 'Immunoproliferative Disorders'}, {'id': 'D007154', 'term': 'Immune System Diseases'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'D013048', 'term': 'Specimen Handling'}, {'id': 'D005440', 'term': 'Fluid Therapy'}, {'id': 'D001706', 'term': 'Biopsy'}, {'id': 'C548400', 'term': 'ixazomib'}, {'id': 'D000077269', 'term': 'Lenalidomide'}, {'id': 'D009682', 'term': 'Magnetic Resonance Spectroscopy'}], 'ancestors': [{'id': 'D019411', 'term': 'Clinical Laboratory Techniques'}, {'id': 'D019937', 'term': 'Diagnostic Techniques and Procedures'}, {'id': 'D003933', 'term': 'Diagnosis'}, {'id': 'D008919', 'term': 'Investigative Techniques'}, {'id': 'D004358', 'term': 'Drug Therapy'}, {'id': 'D013812', 'term': 'Therapeutics'}, {'id': 'D003581', 'term': 'Cytodiagnosis'}, {'id': 'D003584', 'term': 'Cytological Techniques'}, {'id': 'D003949', 'term': 'Diagnostic Techniques, Surgical'}, {'id': 'D013514', 'term': 'Surgical Procedures, Operative'}, {'id': 'D010797', 'term': 'Phthalimides'}, {'id': 'D010795', 'term': 'Phthalic Acids'}, {'id': 'D000146', 'term': 'Acids, Carbocyclic'}, {'id': 'D002264', 'term': 'Carboxylic Acids'}, {'id': 'D009930', 'term': 'Organic Chemicals'}, {'id': 'D010881', 'term': 'Piperidones'}, {'id': 'D010880', 'term': 'Piperidines'}, {'id': 'D006573', 'term': 'Heterocyclic Compounds, 1-Ring'}, {'id': 'D006571', 'term': 'Heterocyclic Compounds'}, {'id': 'D054833', 'term': 'Isoindoles'}, {'id': 'D006574', 'term': 'Heterocyclic Compounds, 2-Ring'}, {'id': 'D000072471', 'term': 'Heterocyclic Compounds, Fused-Ring'}, {'id': 'D013057', 'term': 'Spectrum Analysis'}, {'id': 'D002623', 'term': 'Chemistry Techniques, Analytical'}]}}, 'resultsSection': {'moreInfoModule': {'pointOfContact': {'email': 'eatrials@jimmy.harvard.edu', 'phone': '617-632-3012', 'title': 'Study Statistician', 'organization': 'ECOG-ACRIN Statistical Office'}, 'certainAgreement': {'restrictionType': 'LTE60', 'piSponsorEmployee': False, 'restrictiveAgreement': True}, 'limitationsAndCaveats': {'description': 'Only one patient was enrolled on this study. Due to the concern on confidentiality, individual data is not reported.'}}, 'adverseEventsModule': {'timeFrame': 'Assessed every 4 weeks until 30 days after treatment completion, up to 10 years', 'description': 'Only one patient was enrolled on this study. Due to the concern on confidentiality, individual data is not reported.', 'eventGroups': [{'id': 'EG000', 'title': 'Arm A (Lenalidomide, Ixazomib Citrate)', 'description': 'Patients receive lenalidomide PO QD on days 1-28 and ixazomib citrate PO on days 1, 8, and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo bone marrow aspirate and/or biopsy and PET and CT scan at screening and on study as well as undergo collection of blood samples throughout the trial.\n\nBiospecimen Collection: Undergo collection of blood samples\n\nBone Marrow Aspirate: Undergo bone marrow aspirate\n\nBone Marrow Biopsy: Undergo bone marrow biopsy\n\nComputed Tomography: Undergo CT scan\n\nIxazomib Citrate: Given PO\n\nLenalidomide: Given PO\n\nQuality-of-Life Assessment: Ancillary studies\n\nQuestionnaire Administration: Ancillary studies', 'otherNumAtRisk': 0, 'deathsNumAtRisk': 0, 'otherNumAffected': 0, 'seriousNumAtRisk': 0, 'deathsNumAffected': 0, 'seriousNumAffected': 0}, {'id': 'EG001', 'title': 'Arm B (Lenalidomide, Placebo)', 'description': 'Patients receive lenalidomide PO QD on days 1-28 and a placebo PO on days 1, 8, and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo bone marrow aspirate and/or biopsy and PET and CT scan at screening and on study as well as undergo collection of blood samples throughout the trial.\n\nBiospecimen Collection: Undergo collection of blood samples\n\nBone Marrow Aspirate: Undergo bone marrow aspirate\n\nBone Marrow Biopsy: Undergo bone marrow biopsy\n\nComputed Tomography: Undergo CT scan\n\nLenalidomide: Given PO\n\nPlacebo Administration: Given PO\n\nPositron Emission Tomography: Undergo PET scan\n\nQuality-of-Life Assessment: Ancillary studies\n\nQuestionnaire Administration: Ancillary studies', 'otherNumAtRisk': 0, 'deathsNumAtRisk': 0, 'otherNumAffected': 0, 'seriousNumAtRisk': 0, 'deathsNumAffected': 0, 'seriousNumAffected': 0}], 'frequencyThreshold': '5'}, 'outcomeMeasuresModule': {'outcomeMeasures': [{'type': 'PRIMARY', 'title': 'Overall Survival (OS)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Arm A (Lenalidomide, Ixazomib Citrate)', 'description': 'Patients receive lenalidomide PO QD on days 1-28 and ixazomib citrate PO on days 1, 8, and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo bone marrow aspirate and/or biopsy and PET and CT scan at screening and on study as well as undergo collection of blood samples throughout the trial.\n\nBiospecimen Collection: Undergo collection of blood samples\n\nBone Marrow Aspirate: Undergo bone marrow aspirate\n\nBone Marrow Biopsy: Undergo bone marrow biopsy\n\nComputed Tomography: Undergo CT scan\n\nIxazomib Citrate: Given PO\n\nLenalidomide: Given PO\n\nQuality-of-Life Assessment: Ancillary studies\n\nQuestionnaire Administration: Ancillary studies'}, {'id': 'OG001', 'title': 'Arm B (Lenalidomide, Placebo)', 'description': 'Patients receive lenalidomide PO QD on days 1-28 and a placebo PO on days 1, 8, and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo bone marrow aspirate and/or biopsy and PET and CT scan at screening and on study as well as undergo collection of blood samples throughout the trial.\n\nBiospecimen Collection: Undergo collection of blood samples\n\nBone Marrow Aspirate: Undergo bone marrow aspirate\n\nBone Marrow Biopsy: Undergo bone marrow biopsy\n\nComputed Tomography: Undergo CT scan\n\nLenalidomide: Given PO\n\nPlacebo Administration: Given PO\n\nPositron Emission Tomography: Undergo PET scan\n\nQuality-of-Life Assessment: Ancillary studies\n\nQuestionnaire Administration: Ancillary studies'}], 'timeFrame': 'Assessed every 3 months if patient is <2 years from randomization, every 6 months if patient is 2-5 years from randomization, annually if patient is 5 years or more from randomization.', 'description': 'Overall survival is defined as time from randomization to death or date last known alive.', 'reportingStatus': 'POSTED', 'populationDescription': 'Only one patient was enrolled on this study. Due to the concern on confidentiality, individual data is not reported.'}, {'type': 'SECONDARY', 'title': 'Progression-free Survival (PFS)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Arm A (Lenalidomide, Ixazomib Citrate)', 'description': 'Patients receive lenalidomide PO QD on days 1-28 and ixazomib citrate PO on days 1, 8, and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo bone marrow aspirate and/or biopsy and PET and CT scan at screening and on study as well as undergo collection of blood samples throughout the trial.\n\nBiospecimen Collection: Undergo collection of blood samples\n\nBone Marrow Aspirate: Undergo bone marrow aspirate\n\nBone Marrow Biopsy: Undergo bone marrow biopsy\n\nComputed Tomography: Undergo CT scan\n\nIxazomib Citrate: Given PO\n\nLenalidomide: Given PO\n\nQuality-of-Life Assessment: Ancillary studies\n\nQuestionnaire Administration: Ancillary studies'}, {'id': 'OG001', 'title': 'Arm B (Lenalidomide, Placebo)', 'description': 'Patients receive lenalidomide PO QD on days 1-28 and a placebo PO on days 1, 8, and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo bone marrow aspirate and/or biopsy and PET and CT scan at screening and on study as well as undergo collection of blood samples throughout the trial.\n\nBiospecimen Collection: Undergo collection of blood samples\n\nBone Marrow Aspirate: Undergo bone marrow aspirate\n\nBone Marrow Biopsy: Undergo bone marrow biopsy\n\nComputed Tomography: Undergo CT scan\n\nLenalidomide: Given PO\n\nPlacebo Administration: Given PO\n\nPositron Emission Tomography: Undergo PET scan\n\nQuality-of-Life Assessment: Ancillary studies\n\nQuestionnaire Administration: Ancillary studies'}], 'timeFrame': 'Assessed every 3 months if patient is <2 years from randomization, every 6 months if patient is 2-5 years from randomization, annually if patient is 5 years or more from randomization.', 'description': 'Progression-free survival defined as the time from randomization until the earlier of progression or death due to any cause, or censored at date of last disease evaluation.\n\nProgression is defined as one of the following criteria is met.\n\n* Increase of ≥ 25% from lowest value reported in serum M-component (the absolute increase must be ≥ 0.5 g/dL) and/or urine M-component (the absolute increase must be ≥ 200 mg/ 24 hours).\n* Only in patients without measurable serum and urine M protein levels: the difference between involved and uninvolved FLC levels. The absolute increase must be \\> 10 mg/dL.\n* If the only measurable disease is bone marrow, bone marrow plasma cell percentage: the absolute % must be ≥ 10%.\n* Development of new bone lesions or soft tissue plasmacytomas or ≥ 50% increase from nadir in the size (SPD) of existing bone lesions or soft tissue plasmacytoma or ≥ 50% increase in the longest diameter of a previous lesion \\> 1cm in short axis.', 'reportingStatus': 'POSTED', 'populationDescription': 'Only one patient was enrolled on this study. Due to confidentiality reasons, individual data was not reported.'}, {'type': 'SECONDARY', 'title': 'Best Response on Treatment', 'denoms': [{'units': 'Participants', 'counts': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Arm A (Lenalidomide, Ixazomib Citrate)', 'description': 'Patients receive lenalidomide PO QD on days 1-28 and ixazomib citrate PO on days 1, 8, and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo bone marrow aspirate and/or biopsy and PET and CT scan at screening and on study as well as undergo collection of blood samples throughout the trial.\n\nBiospecimen Collection: Undergo collection of blood samples\n\nBone Marrow Aspirate: Undergo bone marrow aspirate\n\nBone Marrow Biopsy: Undergo bone marrow biopsy\n\nComputed Tomography: Undergo CT scan\n\nIxazomib Citrate: Given PO\n\nLenalidomide: Given PO\n\nQuality-of-Life Assessment: Ancillary studies\n\nQuestionnaire Administration: Ancillary studies'}, {'id': 'OG001', 'title': 'Arm B (Lenalidomide, Placebo)', 'description': 'Patients receive lenalidomide PO QD on days 1-28 and a placebo PO on days 1, 8, and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo bone marrow aspirate and/or biopsy and PET and CT scan at screening and on study as well as undergo collection of blood samples throughout the trial.\n\nBiospecimen Collection: Undergo collection of blood samples\n\nBone Marrow Aspirate: Undergo bone marrow aspirate\n\nBone Marrow Biopsy: Undergo bone marrow biopsy\n\nComputed Tomography: Undergo CT scan\n\nLenalidomide: Given PO\n\nPlacebo Administration: Given PO\n\nPositron Emission Tomography: Undergo PET scan\n\nQuality-of-Life Assessment: Ancillary studies\n\nQuestionnaire Administration: Ancillary studies'}], 'timeFrame': 'Assessed every 3 months if patient is <2 years from randomization, every 6 months if patient is 2-5 years from randomization, annually if patient is 5 years or more from randomization.', 'description': 'Response is evaluated based on standard International Myeloma Working Group (IMWG) criteria and tabulated by category. Response (stringent complete response \\[sCR\\], complete response \\[CR\\], very good partial response \\[VGPR\\]) is defined as below.\n\nsCR: All CR criteria and the following have to be met. Normal serum FLC ratio at two consecutive times and absence of clonal cells in bone marrow by immunohistochemistry or 2- to 4- color flow cytometry. Presence/absence of clonal cells is based upon the κ/λ ratio. An abnormal κ/λ ratio by immunohistochemistry requires a minimum of 100 plasma cells for analysis. An abnormal ratio reflecting presence of an abnormal clone is κ/λ ratio of 4:1 or 1:2.\n\nCR: Complete disappearance of an Mprotein and no evidence of myeloma in the bone marrow.\n\nVGPR: Serum M-protein detectable by immunofixation but not quantifiable on electrophoresis and urine M-protein \\< 100 mg/24 hours', 'reportingStatus': 'POSTED', 'populationDescription': 'Only one patient was enrolled on this study. Due to confidentiality reasons, individual data was not reported.'}, {'type': 'OTHER_PRE_SPECIFIED', 'title': 'Cumulative Dose', 'timeFrame': 'End of treatment, up to 10 years', 'description': 'Cumulative dose will be calculated as the sum of all doses taken across all cycles.', 'reportingStatus': 'NOT_POSTED', 'denomUnitsSelected': 'Participants'}, {'type': 'OTHER_PRE_SPECIFIED', 'title': 'Relative Dose Intensity', 'timeFrame': 'End of treatment, up to 10 years', 'description': 'Relative dose intensity will be calculated as the dose intensity divided by planned dose intensity.', 'reportingStatus': 'NOT_POSTED', 'denomUnitsSelected': 'Participants'}, {'type': 'OTHER_PRE_SPECIFIED', 'title': 'Dose Intensity', 'timeFrame': 'Up to 15 years', 'description': 'Will be calculated as cumulative dose received divided by treatment duration. Will be calculated overall and by cycle. Data will be summarized by treatment arm with descriptive statistics and graphically over time.', 'reportingStatus': 'NOT_POSTED', 'denomUnitsSelected': 'Participants'}, {'type': 'OTHER_PRE_SPECIFIED', 'title': 'Treatment Duration', 'timeFrame': 'End of treatment, up to 10 years', 'description': 'Treatment duration is defined as the time from randomization to date off treatment. Patients who are still on treatment will be censored at the date of last treatment.', 'reportingStatus': 'NOT_POSTED', 'denomUnitsSelected': 'Participants'}, {'type': 'OTHER_PRE_SPECIFIED', 'title': 'Duration of Response', 'timeFrame': 'Assessed every 3 months if patient is <2 years from randomization, every 6 months if patient is 2-5 years from randomization, annually if patient is 5 years or more from randomization.', 'description': 'Duration of response is defined as the time from observed response (VGPR, CR or sCR) to the time of progression in the respective group of responders.', 'reportingStatus': 'NOT_POSTED', 'denomUnitsSelected': 'Participants'}, {'type': 'OTHER_PRE_SPECIFIED', 'title': 'Time to Progression', 'timeFrame': 'Assessed every 3 months if patient is <2 years from randomization, every 6 months if patient is 2-5 years from randomization, annually if patient is 5 years or more from randomization.', 'description': 'Time to progression is defined as the time from randomization to progression. Patients without documented progression will be censored at date of last disease assessment.\n\nProgression is defined as one of the following criteria is met.\n\n* Increase of ≥ 25% from lowest value reported in serum M-component (the absolute increase must be ≥ 0.5 g/dL) and/or urine M-component (the absolute increase must be ≥ 200 mg/ 24 hours).\n* Only in patients without measurable serum and urine M protein levels: the difference between involved and uninvolved FLC levels. The absolute increase must be \\> 10 mg/dL.\n* If the only measurable disease is bone marrow, bone marrow plasma cell percentage: the absolute % must be ≥ 10%.\n* Development of new bone lesions or soft tissue plasmacytomas or ≥ 50% increase from nadir in the size (SPD) of existing bone lesions or soft tissue plasmacytoma or ≥ 50% increase in the longest diameter of a previous lesion \\> 1cm in short axis.', 'reportingStatus': 'NOT_POSTED', 'denomUnitsSelected': 'Participants'}, {'type': 'OTHER_PRE_SPECIFIED', 'title': 'To Determine the Extent and Timing of Neuropathy Associated With the Addition of Ixazomib to Lenalidomide Maintenance on Patient Reported Health-related Quality of Life (QOL) Outcomes.', 'timeFrame': 'Assessed at baseline, end of every 3 cycles for the first 24 cycles, every 6 cycles thereafter up to completion of 48 cycles, and at treatment discontinuation prior to completing 48 cycles. During long-term follow-up, 4 quarterly assessments for 1 year.', 'description': 'Health-related QOL will be assessed with three instruments: 1) the FACT-General (G) functional well-being (FWB) and physical wellbeing (PWB) subscales. Each FACT-G subscale has 7 items. The 14 items are based on a 5-point Likert scale (0-4) resulting in a score ranging from 0 to 56 points with a higher score indicating better health-related QOL; 2) The FACT/GOG-Neurotoxicity Trial Outcomes Index (FACT/GOG-Ntx TOI) comprised of the FWB and PWB subscales plus the neurotoxicity subscale which has 11 items, summing to a score of 0-100; and 3) the FACT-Multiple Myeloma Trial Outcomes Index (FACT-MM TOI) comprised of the FWB and PWB subscales plus the multiple myeloma subscale which has 14 items, summing to a score of 0-112 for the instrument.', 'reportingStatus': 'NOT_POSTED', 'denomUnitsSelected': 'Participants'}, {'type': 'OTHER_PRE_SPECIFIED', 'title': 'To Assess the Impact and Timing of Disease Control With the Addition of Ixazomib to Lenalidomide Maintenance on Patient Reported Healthrelated Quality of Life Outcomes', 'timeFrame': 'Assessed at baseline, end of every 3 cycles for the first 24 cycles, every 6 cycles thereafter up to completion of 48 cycles, and at treatment discontinuation prior to completing 48 cycles. During long-term follow-up, 4 quarterly assessments for 1 year.', 'description': 'Health-related QOL will be assessed with three instruments: 1) the FACT-General (G) functional well-being (FWB) and physical wellbeing (PWB) subscales. Each FACT-G subscale has 7 items. The 14 items are based on a 5-point Likert scale (0-4) resulting in a score ranging from 0 to 56 points with a higher score indicating better health-related QOL; 2) The FACT/GOG-Neurotoxicity Trial Outcomes Index (FACT/GOG-Ntx TOI) comprised of the FWB and PWB subscales plus the neurotoxicity subscale which has 11 items, summing to a score of 0-100; and 3) the FACT-Multiple Myeloma Trial Outcomes Index (FACT-MM TOI) comprised of the FWB and PWB subscales plus the multiple myeloma subscale which has 14 items, summing to a score of 0-112 for the instrument.', 'reportingStatus': 'NOT_POSTED', 'denomUnitsSelected': 'Participants'}, {'type': 'OTHER_PRE_SPECIFIED', 'title': 'Presence, Frequency, Interference, Amount, and/or Severity of Select Patient Reported Outcomes - Common Terminology Criteria for Adverse Events (PRO-CTCAE)', 'timeFrame': 'Assessed every cycle up to cycle 25', 'description': "NCI PRO-CTCAE items will be administered. There are 80 symptomatic AE terms included in the PRO-CTCAE library. Items correspond to 5 attributes measured \\[frequency (F), severity (S), interference (I), presence/absence (P) and amount (A)\\] based on multiple choice questions. Response for each attribute except P which is binary is on a 5-point Likert scale with 5 indicating 'almost constantly' frequency, 'very severe' severity, 'very much' amount or 'very much' interference. For each attribute, recall is the past 7 days. Attributes measured for each symptomatic AE varies and comprise the PRO-CTCAE item library. For this study, 23 symptomatic AEs summing to 38 items have been selected as presented below. There are 10 symptomatic AEs assessed using one item, 11 symptomatic AEs assessed using two items, and 6 symptomatic AEs assessed using three items. The types of items in order of prevalence include severity, interference, frequency, present/not present, and amount. T", 'reportingStatus': 'NOT_POSTED', 'denomUnitsSelected': 'Participants'}, {'type': 'OTHER_PRE_SPECIFIED', 'title': 'Adherence Starts With Knowledge (ASK)-12 Scores', 'timeFrame': 'Assessed at cycles 7, 13, 19, 25, 31, 37, 43 and 49', 'description': "The Adherence Starts with Knowledge Scale (ASK-12) will be used to assess the likelihood that a patient is taking oral medications per protocol. The 12-item questionnaire was derived from the predecessor ASK-20 using a study population of 112 patients with asthma, congestive heart failure or diabetes. In this study, the ASK12 had good internal consistency, and test-retest reliability. The ASK-12 which elicits the same type of information as the Morisky Medication Adherence Scale (MMAS) also demonstrated convergent validity through strong correlation with MMAS-4 (Spearman correlation r = 0.74; p \\< 0.001). The ASK-12 titled 'Taking Medicine What Gets in the Way?' is segmented into 3 sections: inconvenience/forgetfulness (3 items), treatment beliefs (4 items) and behavior (5 items). Response for each item is on a 5-point Likert scale (1-5) with the total score ranging from 12-60 and a higher score representing less likelihood of medication adherence.", 'reportingStatus': 'NOT_POSTED', 'denomUnitsSelected': 'Participants'}, {'type': 'OTHER_PRE_SPECIFIED', 'title': 'To Assess Correlation Among Patient Reported Outcome Measures and Association With Clinical Outcomes.', 'timeFrame': 'Assessed every 3 months if patient is <2 years from randomization, every 6 months if patient is 2-5 years from randomization, annually if patient is 5 years or more from randomization.', 'description': 'The association between patient reported outcome measures and clinical outcomes will be evaluated.', 'reportingStatus': 'NOT_POSTED', 'denomUnitsSelected': 'Participants'}, {'type': 'OTHER_PRE_SPECIFIED', 'title': 'PRO Compliance Rate', 'timeFrame': 'At 10 years', 'description': 'PRO compliance rate is defined as the proportion of patients who submit the given PRO instrument among those eligible at each time point which excludes those missing by design (due to death or disease progression, early treatment discontinuation).', 'reportingStatus': 'NOT_POSTED', 'denomUnitsSelected': 'Participants'}, {'type': 'OTHER_PRE_SPECIFIED', 'title': 'PRO Completion Rate', 'timeFrame': 'Assessed at each cycle, up to 10 years', 'description': "PRO completion rate is defined as the proportion of patients who complete given PRO instrument based on the instrument's scoring system among those eligible at each time point.", 'reportingStatus': 'NOT_POSTED', 'denomUnitsSelected': 'Participants'}, {'type': 'OTHER_PRE_SPECIFIED', 'title': 'To Evaluate the Association Between Baseline 18F-FDG PET/CT and Patient Outcomes.', 'timeFrame': 'Assessed every 3 months if patient is <2 years from randomization, every 6 months if patient is 2-5 years from randomization, annually if patient is 5 years or more from randomization.', 'description': 'Quantitatively, the association between baseline standardized uptake values (SUV) based quantitative 18F-FDG PET/CT parameters (SUVmax, SUVpeak, metabolic tumor volume \\[MTV\\], total lesion glycolysis \\[TLG\\]) and PFS will be analyzed through Cox regression. PFS will be defined as the time from randomization until the earlier of progression or death due to any cause. SUV-based quantitative 18F-FDG PET/CT (qPET) parameters will be analyzed as continuous covariates.', 'reportingStatus': 'NOT_POSTED', 'denomUnitsSelected': 'Participants'}, {'type': 'OTHER_PRE_SPECIFIED', 'title': 'To Compare the Change in Quantitative 18F-FDG PET/CT Parameters Over Time With the Addition of Ixazomib to Lenalidomide', 'timeFrame': 'Assessed at baseline and 1 year', 'description': 'The difference in qPET parameters from the baseline 18FFDG PET/CT to the year 1 18F-FDG PET/CT will be reported by study arm. An analysis of covariance (ANCOVA) model will be used to test for a treatment effect on each qPET parameter, where the baseline qPET parameter value and an indicator for study arm are included as covariates, with the qPET parameter at year 1 as the model outcome.', 'reportingStatus': 'NOT_POSTED', 'denomUnitsSelected': 'Participants'}, {'type': 'OTHER_PRE_SPECIFIED', 'title': 'To Compare Overall Survival (OS) With the Addition of Ixazomib to Lenalidomide Among Baseline 18F-FDG PET/CT-positive and 18F-FDG PET/CT-negative Subgroups.', 'timeFrame': 'Assessed every 3 months if patient is <2 years from randomization, every 6 months if patient is 2-5 years from randomization, annually if patient is 5 years or more from randomization.', 'description': 'Heterogeneity of treatment effect will be assessed at full information, using a two-sided statistical test for interaction between study arm (ixazomib/lenalidomide vs. placebo/lenalidomide) and baseline 18F-FDG PET/CT status (positive/abnormal vs. negative) in a Cox regression model. If the statistical test for interaction is not significant at the 0.05 level, we will conclude that there is not sufficient evidence for heterogeneity of treatment effect; if the statistical test for interaction is significant, estimated treatment hazard ratios for OS (ixazomib arm vs. placebo arm) will be reported separately for baseline 18FFDG PET/CT-positive and 18F-FDG PET/CT-negative subgroups, along with the corresponding 95% confidence intervals. OS will be defined as the time from randomization until death or the date last known alive.', 'reportingStatus': 'NOT_POSTED', 'denomUnitsSelected': 'Participants'}, {'type': 'OTHER_PRE_SPECIFIED', 'title': 'Incidence of Adverse Events', 'timeFrame': 'Assessed at each cycle, up to 10 years', 'description': 'Incidence of adverse events', 'reportingStatus': 'NOT_POSTED', 'denomUnitsSelected': 'Participants'}]}, 'participantFlowModule': {'groups': [{'id': 'FG000', 'title': 'Arm A (Lenalidomide, Ixazomib Citrate)', 'description': 'Patients receive lenalidomide PO QD on days 1-28 and ixazomib citrate PO on days 1, 8, and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo bone marrow aspirate and/or biopsy and PET and CT scan at screening and on study as well as undergo collection of blood samples throughout the trial.\n\nBiospecimen Collection: Undergo collection of blood samples\n\nBone Marrow Aspirate: Undergo bone marrow aspirate\n\nBone Marrow Biopsy: Undergo bone marrow biopsy\n\nComputed Tomography: Undergo CT scan\n\nIxazomib Citrate: Given PO\n\nLenalidomide: Given PO\n\nQuality-of-Life Assessment: Ancillary studies\n\nQuestionnaire Administration: Ancillary studies'}, {'id': 'FG001', 'title': 'Arm B (Lenalidomide, Placebo)', 'description': 'Patients receive lenalidomide PO QD on days 1-28 and a placebo PO on days 1, 8, and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo bone marrow aspirate and/or biopsy and PET and CT scan at screening and on study as well as undergo collection of blood samples throughout the trial.\n\nBiospecimen Collection: Undergo collection of blood samples\n\nBone Marrow Aspirate: Undergo bone marrow aspirate\n\nBone Marrow Biopsy: Undergo bone marrow biopsy\n\nComputed Tomography: Undergo CT scan\n\nLenalidomide: Given PO\n\nPlacebo Administration: Given PO\n\nPositron Emission Tomography: Undergo PET scan\n\nQuality-of-Life Assessment: Ancillary studies\n\nQuestionnaire Administration: Ancillary studies'}], 'periods': [{'title': 'Overall Study', 'milestones': [{'type': 'STARTED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '1'}]}, {'type': 'COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}]}, {'type': 'NOT COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '1'}]}], 'dropWithdraws': [{'type': 'Withdrawal by Subject', 'reasons': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '1'}]}]}], 'recruitmentDetails': 'The study was activated on June 1, 2021 and closed to accrual on March 3, 2023 due to slow accrual.'}, 'baselineCharacteristicsModule': {'denoms': [{'units': 'Participants', 'counts': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}]}], 'groups': [{'id': 'BG000', 'title': 'Arm A (Lenalidomide, Ixazomib Citrate)', 'description': 'Patients receive lenalidomide PO QD on days 1-28 and ixazomib citrate PO on days 1, 8, and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo bone marrow aspirate and/or biopsy and PET and CT scan at screening and on study as well as undergo collection of blood samples throughout the trial.\n\nBiospecimen Collection: Undergo collection of blood samples\n\nBone Marrow Aspirate: Undergo bone marrow aspirate\n\nBone Marrow Biopsy: Undergo bone marrow biopsy\n\nComputed Tomography: Undergo CT scan\n\nIxazomib Citrate: Given PO\n\nLenalidomide: Given PO\n\nQuality-of-Life Assessment: Ancillary studies\n\nQuestionnaire Administration: Ancillary studies'}, {'id': 'BG001', 'title': 'Arm B (Lenalidomide, Placebo)', 'description': 'Patients receive lenalidomide PO QD on days 1-28 and a placebo PO on days 1, 8, and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo bone marrow aspirate and/or biopsy and PET and CT scan at screening and on study as well as undergo collection of blood samples throughout the trial.\n\nBiospecimen Collection: Undergo collection of blood samples\n\nBone Marrow Aspirate: Undergo bone marrow aspirate\n\nBone Marrow Biopsy: Undergo bone marrow biopsy\n\nComputed Tomography: Undergo CT scan\n\nLenalidomide: Given PO\n\nPlacebo Administration: Given PO\n\nPositron Emission Tomography: Undergo PET scan\n\nQuality-of-Life Assessment: Ancillary studies\n\nQuestionnaire Administration: Ancillary studies'}, {'id': 'BG002', 'title': 'Total', 'description': 'Total of all reporting groups'}], 'measures': [{'title': 'Age, Continuous'}, {'title': 'Sex: Female, Male', 'classes': [{'categories': [{'title': 'Female'}, {'title': 'Male'}]}]}, {'title': 'Ethnicity (NIH/OMB)', 'classes': [{'categories': [{'title': 'Hispanic or Latino'}, {'title': 'Not Hispanic or Latino'}, {'title': 'Unknown or Not Reported'}]}]}, {'title': 'Race (NIH/OMB)', 'classes': [{'categories': [{'title': 'American Indian or Alaska Native'}, {'title': 'Asian'}, {'title': 'Native Hawaiian or Other Pacific Islander'}, {'title': 'Black or African American'}, {'title': 'White'}, {'title': 'More than one race'}, {'title': 'Unknown or Not Reported'}]}]}], 'populationDescription': 'Only one patient was enrolled on this study. Due to the concern on confidentiality, individual data is not reported.'}}, 'documentSection': {'largeDocumentModule': {'largeDocs': [{'date': '2023-01-04', 'size': 1072046, 'label': 'Study Protocol and Statistical Analysis Plan', 'hasIcf': False, 'hasSap': True, 'filename': 'Prot_SAP_000.pdf', 'typeAbbrev': 'Prot_SAP', 'uploadDate': '2024-07-05T09:18', 'hasProtocol': True}, {'date': '2023-01-04', 'size': 301532, 'label': 'Informed Consent Form', 'hasIcf': True, 'hasSap': False, 'filename': 'ICF_001.pdf', 'typeAbbrev': 'ICF', 'uploadDate': '2025-05-08T07:40', 'hasProtocol': False}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE3'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'DOUBLE', 'whoMasked': ['PARTICIPANT', 'INVESTIGATOR']}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'PARALLEL'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 1}}, 'statusModule': {'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '2022-02-16', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2025-05', 'completionDateStruct': {'date': '2025-01-31', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2025-05-08', 'studyFirstSubmitDate': '2019-05-07', 'resultsFirstSubmitDate': '2024-07-05', 'studyFirstSubmitQcDate': '2019-05-07', 'lastUpdatePostDateStruct': {'date': '2025-05-23', 'type': 'ACTUAL'}, 'resultsFirstSubmitQcDate': '2024-07-05', 'studyFirstPostDateStruct': {'date': '2019-05-08', 'type': 'ACTUAL'}, 'resultsFirstPostDateStruct': {'date': '2024-08-01', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2023-08-06', 'type': 'ACTUAL'}}, 'outcomesModule': {'otherOutcomes': [{'measure': 'Cumulative Dose', 'timeFrame': 'End of treatment, up to 10 years', 'description': 'Cumulative dose will be calculated as the sum of all doses taken across all cycles.'}, {'measure': 'Relative Dose Intensity', 'timeFrame': 'End of treatment, up to 10 years', 'description': 'Relative dose intensity will be calculated as the dose intensity divided by planned dose intensity.'}, {'measure': 'Dose Intensity', 'timeFrame': 'Up to 15 years', 'description': 'Will be calculated as cumulative dose received divided by treatment duration. Will be calculated overall and by cycle. Data will be summarized by treatment arm with descriptive statistics and graphically over time.'}, {'measure': 'Treatment Duration', 'timeFrame': 'End of treatment, up to 10 years', 'description': 'Treatment duration is defined as the time from randomization to date off treatment. Patients who are still on treatment will be censored at the date of last treatment.'}, {'measure': 'Duration of Response', 'timeFrame': 'Assessed every 3 months if patient is <2 years from randomization, every 6 months if patient is 2-5 years from randomization, annually if patient is 5 years or more from randomization.', 'description': 'Duration of response is defined as the time from observed response (VGPR, CR or sCR) to the time of progression in the respective group of responders.'}, {'measure': 'Time to Progression', 'timeFrame': 'Assessed every 3 months if patient is <2 years from randomization, every 6 months if patient is 2-5 years from randomization, annually if patient is 5 years or more from randomization.', 'description': 'Time to progression is defined as the time from randomization to progression. Patients without documented progression will be censored at date of last disease assessment.\n\nProgression is defined as one of the following criteria is met.\n\n* Increase of ≥ 25% from lowest value reported in serum M-component (the absolute increase must be ≥ 0.5 g/dL) and/or urine M-component (the absolute increase must be ≥ 200 mg/ 24 hours).\n* Only in patients without measurable serum and urine M protein levels: the difference between involved and uninvolved FLC levels. The absolute increase must be \\> 10 mg/dL.\n* If the only measurable disease is bone marrow, bone marrow plasma cell percentage: the absolute % must be ≥ 10%.\n* Development of new bone lesions or soft tissue plasmacytomas or ≥ 50% increase from nadir in the size (SPD) of existing bone lesions or soft tissue plasmacytoma or ≥ 50% increase in the longest diameter of a previous lesion \\> 1cm in short axis.'}, {'measure': 'To Determine the Extent and Timing of Neuropathy Associated With the Addition of Ixazomib to Lenalidomide Maintenance on Patient Reported Health-related Quality of Life (QOL) Outcomes.', 'timeFrame': 'Assessed at baseline, end of every 3 cycles for the first 24 cycles, every 6 cycles thereafter up to completion of 48 cycles, and at treatment discontinuation prior to completing 48 cycles. During long-term follow-up, 4 quarterly assessments for 1 year.', 'description': 'Health-related QOL will be assessed with three instruments: 1) the FACT-General (G) functional well-being (FWB) and physical wellbeing (PWB) subscales. Each FACT-G subscale has 7 items. The 14 items are based on a 5-point Likert scale (0-4) resulting in a score ranging from 0 to 56 points with a higher score indicating better health-related QOL; 2) The FACT/GOG-Neurotoxicity Trial Outcomes Index (FACT/GOG-Ntx TOI) comprised of the FWB and PWB subscales plus the neurotoxicity subscale which has 11 items, summing to a score of 0-100; and 3) the FACT-Multiple Myeloma Trial Outcomes Index (FACT-MM TOI) comprised of the FWB and PWB subscales plus the multiple myeloma subscale which has 14 items, summing to a score of 0-112 for the instrument.'}, {'measure': 'To Assess the Impact and Timing of Disease Control With the Addition of Ixazomib to Lenalidomide Maintenance on Patient Reported Healthrelated Quality of Life Outcomes', 'timeFrame': 'Assessed at baseline, end of every 3 cycles for the first 24 cycles, every 6 cycles thereafter up to completion of 48 cycles, and at treatment discontinuation prior to completing 48 cycles. During long-term follow-up, 4 quarterly assessments for 1 year.', 'description': 'Health-related QOL will be assessed with three instruments: 1) the FACT-General (G) functional well-being (FWB) and physical wellbeing (PWB) subscales. Each FACT-G subscale has 7 items. The 14 items are based on a 5-point Likert scale (0-4) resulting in a score ranging from 0 to 56 points with a higher score indicating better health-related QOL; 2) The FACT/GOG-Neurotoxicity Trial Outcomes Index (FACT/GOG-Ntx TOI) comprised of the FWB and PWB subscales plus the neurotoxicity subscale which has 11 items, summing to a score of 0-100; and 3) the FACT-Multiple Myeloma Trial Outcomes Index (FACT-MM TOI) comprised of the FWB and PWB subscales plus the multiple myeloma subscale which has 14 items, summing to a score of 0-112 for the instrument.'}, {'measure': 'Presence, Frequency, Interference, Amount, and/or Severity of Select Patient Reported Outcomes - Common Terminology Criteria for Adverse Events (PRO-CTCAE)', 'timeFrame': 'Assessed every cycle up to cycle 25', 'description': "NCI PRO-CTCAE items will be administered. There are 80 symptomatic AE terms included in the PRO-CTCAE library. Items correspond to 5 attributes measured \\[frequency (F), severity (S), interference (I), presence/absence (P) and amount (A)\\] based on multiple choice questions. Response for each attribute except P which is binary is on a 5-point Likert scale with 5 indicating 'almost constantly' frequency, 'very severe' severity, 'very much' amount or 'very much' interference. For each attribute, recall is the past 7 days. Attributes measured for each symptomatic AE varies and comprise the PRO-CTCAE item library. For this study, 23 symptomatic AEs summing to 38 items have been selected as presented below. There are 10 symptomatic AEs assessed using one item, 11 symptomatic AEs assessed using two items, and 6 symptomatic AEs assessed using three items. The types of items in order of prevalence include severity, interference, frequency, present/not present, and amount. T"}, {'measure': 'Adherence Starts With Knowledge (ASK)-12 Scores', 'timeFrame': 'Assessed at cycles 7, 13, 19, 25, 31, 37, 43 and 49', 'description': "The Adherence Starts with Knowledge Scale (ASK-12) will be used to assess the likelihood that a patient is taking oral medications per protocol. The 12-item questionnaire was derived from the predecessor ASK-20 using a study population of 112 patients with asthma, congestive heart failure or diabetes. In this study, the ASK12 had good internal consistency, and test-retest reliability. The ASK-12 which elicits the same type of information as the Morisky Medication Adherence Scale (MMAS) also demonstrated convergent validity through strong correlation with MMAS-4 (Spearman correlation r = 0.74; p \\< 0.001). The ASK-12 titled 'Taking Medicine What Gets in the Way?' is segmented into 3 sections: inconvenience/forgetfulness (3 items), treatment beliefs (4 items) and behavior (5 items). Response for each item is on a 5-point Likert scale (1-5) with the total score ranging from 12-60 and a higher score representing less likelihood of medication adherence."}, {'measure': 'To Assess Correlation Among Patient Reported Outcome Measures and Association With Clinical Outcomes.', 'timeFrame': 'Assessed every 3 months if patient is <2 years from randomization, every 6 months if patient is 2-5 years from randomization, annually if patient is 5 years or more from randomization.', 'description': 'The association between patient reported outcome measures and clinical outcomes will be evaluated.'}, {'measure': 'PRO Compliance Rate', 'timeFrame': 'At 10 years', 'description': 'PRO compliance rate is defined as the proportion of patients who submit the given PRO instrument among those eligible at each time point which excludes those missing by design (due to death or disease progression, early treatment discontinuation).'}, {'measure': 'PRO Completion Rate', 'timeFrame': 'Assessed at each cycle, up to 10 years', 'description': "PRO completion rate is defined as the proportion of patients who complete given PRO instrument based on the instrument's scoring system among those eligible at each time point."}, {'measure': 'To Evaluate the Association Between Baseline 18F-FDG PET/CT and Patient Outcomes.', 'timeFrame': 'Assessed every 3 months if patient is <2 years from randomization, every 6 months if patient is 2-5 years from randomization, annually if patient is 5 years or more from randomization.', 'description': 'Quantitatively, the association between baseline standardized uptake values (SUV) based quantitative 18F-FDG PET/CT parameters (SUVmax, SUVpeak, metabolic tumor volume \\[MTV\\], total lesion glycolysis \\[TLG\\]) and PFS will be analyzed through Cox regression. PFS will be defined as the time from randomization until the earlier of progression or death due to any cause. SUV-based quantitative 18F-FDG PET/CT (qPET) parameters will be analyzed as continuous covariates.'}, {'measure': 'To Compare the Change in Quantitative 18F-FDG PET/CT Parameters Over Time With the Addition of Ixazomib to Lenalidomide', 'timeFrame': 'Assessed at baseline and 1 year', 'description': 'The difference in qPET parameters from the baseline 18FFDG PET/CT to the year 1 18F-FDG PET/CT will be reported by study arm. An analysis of covariance (ANCOVA) model will be used to test for a treatment effect on each qPET parameter, where the baseline qPET parameter value and an indicator for study arm are included as covariates, with the qPET parameter at year 1 as the model outcome.'}, {'measure': 'To Compare Overall Survival (OS) With the Addition of Ixazomib to Lenalidomide Among Baseline 18F-FDG PET/CT-positive and 18F-FDG PET/CT-negative Subgroups.', 'timeFrame': 'Assessed every 3 months if patient is <2 years from randomization, every 6 months if patient is 2-5 years from randomization, annually if patient is 5 years or more from randomization.', 'description': 'Heterogeneity of treatment effect will be assessed at full information, using a two-sided statistical test for interaction between study arm (ixazomib/lenalidomide vs. placebo/lenalidomide) and baseline 18F-FDG PET/CT status (positive/abnormal vs. negative) in a Cox regression model. If the statistical test for interaction is not significant at the 0.05 level, we will conclude that there is not sufficient evidence for heterogeneity of treatment effect; if the statistical test for interaction is significant, estimated treatment hazard ratios for OS (ixazomib arm vs. placebo arm) will be reported separately for baseline 18FFDG PET/CT-positive and 18F-FDG PET/CT-negative subgroups, along with the corresponding 95% confidence intervals. OS will be defined as the time from randomization until death or the date last known alive.'}, {'measure': 'Incidence of Adverse Events', 'timeFrame': 'Assessed at each cycle, up to 10 years', 'description': 'Incidence of adverse events'}], 'primaryOutcomes': [{'measure': 'Overall Survival (OS)', 'timeFrame': 'Assessed every 3 months if patient is <2 years from randomization, every 6 months if patient is 2-5 years from randomization, annually if patient is 5 years or more from randomization.', 'description': 'Overall survival is defined as time from randomization to death or date last known alive.'}], 'secondaryOutcomes': [{'measure': 'Progression-free Survival (PFS)', 'timeFrame': 'Assessed every 3 months if patient is <2 years from randomization, every 6 months if patient is 2-5 years from randomization, annually if patient is 5 years or more from randomization.', 'description': 'Progression-free survival defined as the time from randomization until the earlier of progression or death due to any cause, or censored at date of last disease evaluation.\n\nProgression is defined as one of the following criteria is met.\n\n* Increase of ≥ 25% from lowest value reported in serum M-component (the absolute increase must be ≥ 0.5 g/dL) and/or urine M-component (the absolute increase must be ≥ 200 mg/ 24 hours).\n* Only in patients without measurable serum and urine M protein levels: the difference between involved and uninvolved FLC levels. The absolute increase must be \\> 10 mg/dL.\n* If the only measurable disease is bone marrow, bone marrow plasma cell percentage: the absolute % must be ≥ 10%.\n* Development of new bone lesions or soft tissue plasmacytomas or ≥ 50% increase from nadir in the size (SPD) of existing bone lesions or soft tissue plasmacytoma or ≥ 50% increase in the longest diameter of a previous lesion \\> 1cm in short axis.'}, {'measure': 'Best Response on Treatment', 'timeFrame': 'Assessed every 3 months if patient is <2 years from randomization, every 6 months if patient is 2-5 years from randomization, annually if patient is 5 years or more from randomization.', 'description': 'Response is evaluated based on standard International Myeloma Working Group (IMWG) criteria and tabulated by category. Response (stringent complete response \\[sCR\\], complete response \\[CR\\], very good partial response \\[VGPR\\]) is defined as below.\n\nsCR: All CR criteria and the following have to be met. Normal serum FLC ratio at two consecutive times and absence of clonal cells in bone marrow by immunohistochemistry or 2- to 4- color flow cytometry. Presence/absence of clonal cells is based upon the κ/λ ratio. An abnormal κ/λ ratio by immunohistochemistry requires a minimum of 100 plasma cells for analysis. An abnormal ratio reflecting presence of an abnormal clone is κ/λ ratio of 4:1 or 1:2.\n\nCR: Complete disappearance of an Mprotein and no evidence of myeloma in the bone marrow.\n\nVGPR: Serum M-protein detectable by immunofixation but not quantifiable on electrophoresis and urine M-protein \\< 100 mg/24 hours'}]}, 'oversightModule': {'oversightHasDmc': False, 'isFdaRegulatedDrug': True, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'conditions': ['Multiple Myeloma']}, 'descriptionModule': {'briefSummary': 'This phase III trial studies how well lenalidomide in combination with ixazomib works compared to lenalidomide alone in treating patients with evidence of residual multiple myeloma after stem cell transplantation. Lenalidomide may help shrink or slow the growth of multiple myeloma. Ixazomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving lenalidomide and ixazomib together may work better than giving lenalidomide alone in treating patients with evidence of residual multiple myeloma after a stem cell transplantation.', 'detailedDescription': 'PRIMARY OBJECTIVE:\n\nI. To evaluate whether escalating maintenance therapy with the addition of ixazomib citrate (ixazomib) to lenalidomide improves overall survival (OS) among patients who are minimal residual disease (MRD) positive after approximately 1 year of lenalidomide maintenance following an early stem cell transplant (=\\< 12 months from diagnosis).\n\nSECONDARY OBJECTIVES:\n\nI. To establish whether progression-free survival (PFS) is superior with the addition of ixazomib to lenalidomide maintenance.\n\nII. To evaluate best response on treatment and compare response rates between arms.\n\nIII. To evaluate the safety profile of ixazomib added to lenalidomide and compare toxicity rates between arms.\n\nEXPLORATORY OBJECTIVES:\n\nI. To measure treatment exposure and adherence. II. To estimate treatment duration, duration of response and time to progression.\n\nPATIENT-REPORTED OUTCOMES (PRO) OBJECTIVES:\n\nI. To quantify the extent to which the addition of ixazomib to lenalidomide maintenance contributes to neuropathy and associated physical and functional impairments. (Primary) II. To assess the impact of the addition of ixazomib to lenalidomide maintenance on disease control and associated physical and functional well-being. (Primary) III. To evaluate time to worsening and recovery rate related to neuropathy. (Secondary) IV. To evaluate time to improvement and response rate related to disease control. (Secondary) V. To evaluate attributes of select patient reported treatment-emergent symptomatic adverse events (Patient-Reported Outcomes - Common Terminology Criteria for Adverse Events \\[PRO-CTCAE\\]) longitudinally and compare responses with provider-reported adverse events. (Exploratory) VI. To measure the likelihood of medication adherence and examine the relationship with treatment exposure. (Exploratory) VII. To assess correlation among patient reported outcome measures and association with clinical outcomes. (Exploratory) VIII. To tabulate PRO compliance and completion rates. (Exploratory)\n\nIMAGING OBJECTIVES:\n\nI. To evaluate the association between baseline fludeoxyglucose F-18 (18F-FDG)-positron emission tomography (PET)/computed tomography (CT) and patient outcomes.\n\nII. To compare overall survival (OS) with the addition of ixazomib to lenalidomide among baseline 18F-FDG PET/CT-positive and 18F-FDG PET/CT -negative subgroups.\n\nIII. To compare the change in quantitative 18F-FDG PET/CT parameters over time with the addition of ixazomib to lenalidomide.\n\nOUTLINE: Patients are randomized to 1 of 2 arms.\n\nARM A: Patients receive lenalidomide orally (PO) once daily (QD) on days 1-28 and ixazomib citrate PO on days 1, 8, and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo bone marrow aspirate and/or biopsy and positron emission tomography (PET) and computed tomography (CT) scan at screening and on study as well as undergo collection of blood samples throughout the trial.\n\nARM B: Patients receive lenalidomide PO QD on days 1-28 and a placebo PO on days 1, 8, and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo bone marrow aspirate and/or biopsy and PET and CT scan at screening and on study as well as undergo collection of blood samples throughout the trial.\n\nAfter completion of study treatment, patients are followed up every 3 months if \\< 2 years from study entry, every 6 months if 2-5 years from study entry, then every 12 months for up to 10 years from study entry.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'minimumAge': '18 Years', 'healthyVolunteers': False, 'eligibilityCriteria': "Inclusion Criteria:\n\n* STEP 0: PRE-REGISTRATION\n* Patient must be \\>= 18 years of age\n* Patient must be previously diagnosed with multiple myeloma (MM) and be on lenalidomide maintenance with \\>= 5mg daily for at least 6 months and no more than 18 months after an early autologous stem cell transplantation (SCT =\\< 12 months of diagnosis). Patient must not be off lenalidomide maintenance therapy for more than 30 days prior to start of treatment on Step 1 of this protocol\n* Patient must be able to undergo a diagnostic bone marrow aspirate following pre-registration to Step 0\n\n * NOTE: A bone marrow aspirate specimen must be submitted to Mayo Clinic Hematology Laboratory for central assessment of minimal residual disease (MRD) status to confirm patient's eligibility for Step 1 randomization. Mayo Clinic will forward results to the submitting institution within three (3) business days of receipt of the bone marrow specimen\n* Patient must have an Eastern Cooperative Oncology Group (ECOG) performance status 0, 1, or 2\n* Patient must have been able to maintain at least 5mg daily dose of lenalidomide without growth factor support\n* Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial\n* STEP 1 RANDOMIZATION\n* Patient must meet Step 0 eligibility criteria at the time of Step 1 randomization\n* Patients must have evidence of residual disease by central MRD testing or by presence of monoclonal protein in serum or urine\n* Patient must have serum protein electrophoresis (SPEP), urine protein electrophoresis (UPEP), and serum free light chain (FLC) performed =\\< 28 days prior to randomization\n\n * NOTE: UPEP (on a 24-hour collection) is required, no substitute method is acceptable. Urine must be followed monthly if the baseline urine M-spike is \\>= 200 mg/24 hour (hr). Please note that if both serum and urine M-components are present, both must be followed in order to evaluate response\n* Hemoglobin \\>= 8 g/dL (obtained =\\< 14 days prior to randomization)\n* Untransfused platelet count \\>= 75,000 cells/mm\\^3 (obtained =\\< 14 days prior to randomization)\n* Absolute neutrophil count (ANC) \\>= 1000 cells/mm\\^3 (obtained =\\< 14 days prior to randomization)\n* Calculated creatinine clearance \\>= 30 mL/min (obtained =\\< 14 days prior to randomization)\n* Total bilirubin =\\< 1.5 times the upper limit of normal (ULN) (obtained =\\< 14 days prior to randomization)\n* Serum glutamate pyruvate transaminase (SGPT) (alanine aminotransferase \\[ALT\\]) and serum glutamic oxaloacetic transaminase (SGOT) (aspartate aminotransferase \\[AST\\]) =\\< 3 times the upper limit of normal (ULN) (obtained =\\< 14 days prior to randomization)\n* Patient must agree to register into the mandatory Revlimid Risk Evaluation and Mitigation Strategies (REMS) registered trademark program and be willing and able to comply with the requirements of Revlimid REMS registered trademark\n* Patients of childbearing potential must either abstain from sexual intercourse for the duration of their participation in the study or agree to use TWO acceptable methods of birth control, one highly effective method and one additional effective method AT THE SAME TIME for 1) at least 28 days before starting study treatment; 2) while participating in the study; 3) during dose interruptions; and 4) for at least 90 days after the last dose of protocol treatment. Patients must also agree to not breastfeed during this same time period. Men must agree to either abstain from sexual intercourse for the duration of their participation in the study or use a latex condom during sexual contact with a partner of childbearing potential while participating in the study and for 90 days after the last dose of protocol treatment even if they have had a successful vasectomy. Patients must also agree to abstain from donating sperm while on study treatment and for 28 days after the last dose of protocol treatment even if they have had a successful vasectomy. All patients must agree to abstain from donating blood during study participation and for at least 28 days after the last dose of protocol treatment\n\nExclusion Criteria:\n\n* Patient must not have primary refractory or progressive disease on a proteasome inhibitor-based regimen during induction therapy prior to stem cell transplant\n* Patient must not be on other concurrent chemotherapy, or any ancillary therapy considered investigational\n\n * NOTE: Bisphosphonates are considered to be supportive care rather than therapy and are allowed while on protocol treatment\n* Patient must not have uncontrolled psychiatric illness or social situations that would limit compliance with study requirements\n* Patient must not have another malignancy requiring treatment or have received treatment within two years before pre-registration or previously diagnosed with another malignancy and have any evidence of residual disease. Patients with non-melanoma skin cancer or carcinoma in situ of any type are not excluded if they have undergone complete resection\n* Patients must not have known gastrointestinal (GI) disease or GI procedure that could interfere with the oral absorption or tolerance of ixazomib or lenalidomide including difficulty swallowing\n* Patient must not have known hepatitis B surface antigen-positive status or known or suspected active hepatitis C infection, but testing specifically for the trial is not required\n* Patient must not be off lenalidomide maintenance therapy for more than 30 days prior to start of treatment on Step 1 of this protocol\n* Patients must not have grade 2 or higher peripheral neuropathy or grade 1 peripheral neuropathy with pain per Common Terminology Criteria for Adverse Events (CTCAE)\n* Patients must not have uncontrolled intercurrent illness\n* Patients must not have grade 2 or higher diarrhea per CTCAE in the absence of antidiarrheals\n* Patients must not have been on systemic treatment, within 14 days before the first dose of ixazomib, with strong CYP3A inducers (such as rifampin, rifapentine, rifabutin, carbamazepine, phenytoin, phenobarbital), or use of St. John's wort\n* Patient must not be pregnant due to potential harm to the fetus from ixazomib and lenalidomide. All patients of childbearing potential must have a blood test or urine study with a sensitivity of at least 25 mIU/mL within 10-14 days prior to the first dose of lenalidomide and again within 24 hours prior to the first dose of lenalidomide. Patients of childbearing potential must also agree to ongoing pregnancy testing while on treatment. A patient of childbearing potential is defined as anyone, regardless of sexual orientation or whether they have undergone tubal ligation, who meets the following criteria: 1) has achieved menarche at some point, 2) has not undergone a hysterectomy or bilateral oophorectomy, or 3) has not been naturally postmenopausal (amenorrhea following cancer therapy does not rule out childbearing potential) for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months)"}, 'identificationModule': {'nctId': 'NCT03941860', 'briefTitle': 'Testing the Addition of Ixazomib/Placebo to Lenalidomide in Patients With Evidence of Residual Multiple Myeloma, OPTIMUM Trial', 'organization': {'class': 'NIH', 'fullName': 'National Cancer Institute (NCI)'}, 'officialTitle': 'Optimizing Prolonged Treatment In Myeloma Using MRD Assessment (OPTIMUM)', 'orgStudyIdInfo': {'id': 'NCI-2019-02790'}, 'secondaryIdInfos': [{'id': 'NCI-2019-02790', 'type': 'REGISTRY', 'domain': 'CTRP (Clinical Trial Reporting Program)'}, {'id': 'EAA171', 'type': 'OTHER', 'domain': 'ECOG-ACRIN Cancer Research Group'}, {'id': 'EAA171', 'type': 'OTHER', 'domain': 'CTEP'}, {'id': 'U10CA180820', 'link': 'https://reporter.nih.gov/quickSearch/U10CA180820', 'type': 'NIH'}]}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'Arm A (lenalidomide, ixazomib citrate)', 'description': 'Patients receive lenalidomide PO QD on days 1-28 and ixazomib citrate PO on days 1, 8, and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo bone marrow aspirate and/or biopsy and PET and CT scan at screening and on study as well as undergo collection of blood samples throughout the trial.', 'interventionNames': ['Procedure: Biospecimen Collection', 'Procedure: Bone Marrow Aspirate', 'Procedure: Bone Marrow Biopsy', 'Procedure: Computed Tomography', 'Drug: Ixazomib Citrate', 'Drug: Lenalidomide', 'Other: Quality-of-Life Assessment', 'Other: Questionnaire Administration']}, {'type': 'PLACEBO_COMPARATOR', 'label': 'Arm B (lenalidomide, placebo)', 'description': 'Patients receive lenalidomide PO QD on days 1-28 and a placebo PO on days 1, 8, and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo bone marrow aspirate and/or biopsy and PET and CT scan at screening and on study as well as undergo collection of blood samples throughout the trial.', 'interventionNames': ['Procedure: Biospecimen Collection', 'Procedure: Bone Marrow Aspirate', 'Procedure: Bone Marrow Biopsy', 'Procedure: Computed Tomography', 'Drug: Lenalidomide', 'Other: Placebo Administration', 'Procedure: Positron Emission Tomography', 'Other: Quality-of-Life Assessment', 'Other: Questionnaire Administration']}], 'interventions': [{'name': 'Biospecimen Collection', 'type': 'PROCEDURE', 'otherNames': ['Biological Sample Collection', 'Biospecimen Collected', 'Specimen Collection'], 'description': 'Undergo collection of blood samples', 'armGroupLabels': ['Arm A (lenalidomide, ixazomib citrate)', 'Arm B (lenalidomide, placebo)']}, {'name': 'Bone Marrow Aspirate', 'type': 'PROCEDURE', 'otherNames': ['BONE MARROW, LIQUID', 'Human Bone Marrow Aspirate'], 'description': 'Undergo bone marrow aspirate', 'armGroupLabels': ['Arm A (lenalidomide, ixazomib citrate)', 'Arm B (lenalidomide, placebo)']}, {'name': 'Bone Marrow Biopsy', 'type': 'PROCEDURE', 'otherNames': ['Biopsy of Bone Marrow', 'Biopsy, Bone Marrow'], 'description': 'Undergo bone marrow biopsy', 'armGroupLabels': ['Arm A (lenalidomide, ixazomib citrate)', 'Arm B (lenalidomide, placebo)']}, {'name': 'Computed Tomography', 'type': 'PROCEDURE', 'otherNames': ['CAT', 'CAT Scan', 'Computed Axial Tomography', 'Computerized Axial Tomography', 'Computerized axial tomography (procedure)', 'Computerized Tomography', 'Computerized Tomography (CT) scan', 'CT', 'CT Scan', 'tomography'], 'description': 'Undergo CT scan', 'armGroupLabels': ['Arm A (lenalidomide, ixazomib citrate)', 'Arm B (lenalidomide, placebo)']}, {'name': 'Ixazomib Citrate', 'type': 'DRUG', 'otherNames': ['MLN 9708', 'MLN-9708', 'MLN9708', 'Ninlaro'], 'description': 'Given PO', 'armGroupLabels': ['Arm A (lenalidomide, ixazomib citrate)']}, {'name': 'Lenalidomide', 'type': 'DRUG', 'otherNames': ['CC 5013', 'CC-5013', 'CC5013', 'CDC 501', 'Revlimid'], 'description': 'Given PO', 'armGroupLabels': ['Arm A (lenalidomide, ixazomib citrate)', 'Arm B (lenalidomide, placebo)']}, {'name': 'Placebo Administration', 'type': 'OTHER', 'description': 'Given PO', 'armGroupLabels': ['Arm B (lenalidomide, placebo)']}, {'name': 'Positron Emission Tomography', 'type': 'PROCEDURE', 'otherNames': ['Medical Imaging, Positron Emission Tomography', 'PET', 'PET Scan', 'Positron emission tomography (procedure)', 'Positron Emission Tomography Scan', 'Positron-Emission Tomography', 'proton magnetic resonance spectroscopic imaging', 'PT'], 'description': 'Undergo PET scan', 'armGroupLabels': ['Arm B (lenalidomide, placebo)']}, {'name': 'Quality-of-Life Assessment', 'type': 'OTHER', 'otherNames': ['Quality of Life Assessment'], 'description': 'Ancillary studies', 'armGroupLabels': ['Arm A (lenalidomide, ixazomib citrate)', 'Arm B (lenalidomide, placebo)']}, {'name': 'Questionnaire Administration', 'type': 'OTHER', 'description': 'Ancillary studies', 'armGroupLabels': ['Arm A (lenalidomide, ixazomib citrate)', 'Arm B (lenalidomide, placebo)']}]}, 'contactsLocationsModule': {'locations': [{'zip': '85004', 'city': 'Phoenix', 'state': 'Arizona', 'country': 'United States', 'facility': "Cancer Center at Saint Joseph's", 'geoPoint': {'lat': 33.44838, 'lon': -112.07404}}, {'zip': '71913', 'city': 'Hot Springs', 'state': 'Arkansas', 'country': 'United States', 'facility': 'CHI Saint Vincent Cancer Center Hot Springs', 'geoPoint': {'lat': 34.5037, 'lon': -93.05518}}, {'zip': '93420', 'city': 'Arroyo Grande', 'state': 'California', 'country': 'United States', 'facility': 'Mission Hope Medical Oncology - Arroyo Grande', 'geoPoint': {'lat': 35.11859, 'lon': -120.59073}}, {'zip': '93401', 'city': 'San Luis Obispo', 'state': 'California', 'country': 'United States', 'facility': 'Pacific Central Coast Health Center-San Luis Obispo', 'geoPoint': {'lat': 35.28275, 'lon': -120.65962}}, {'zip': '93444', 'city': 'Santa Maria', 'state': 'California', 'country': 'United States', 'facility': 'Mission Hope Medical Oncology - Santa Maria', 'geoPoint': {'lat': 34.95303, 'lon': -120.43572}}, {'zip': '80907', 'city': 'Colorado Springs', 'state': 'Colorado', 'country': 'United States', 'facility': 'Penrose-Saint Francis Healthcare', 'geoPoint': {'lat': 38.83388, 'lon': -104.82136}}, {'zip': '80907', 'city': 'Colorado Springs', 'state': 'Colorado', 'country': 'United States', 'facility': 'Rocky Mountain Cancer Centers-Penrose', 'geoPoint': {'lat': 38.83388, 'lon': -104.82136}}, {'zip': '80210', 'city': 'Denver', 'state': 'Colorado', 'country': 'United States', 'facility': 'AdventHealth Porter', 'geoPoint': {'lat': 39.73915, 'lon': -104.9847}}, {'zip': '81301', 'city': 'Durango', 'state': 'Colorado', 'country': 'United States', 'facility': 'Mercy Medical Center', 'geoPoint': {'lat': 37.27528, 'lon': -107.88007}}, {'zip': '81301', 'city': 'Durango', 'state': 'Colorado', 'country': 'United States', 'facility': 'Southwest Oncology PC', 'geoPoint': {'lat': 37.27528, 'lon': -107.88007}}, {'zip': '80228', 'city': 'Lakewood', 'state': 'Colorado', 'country': 'United States', 'facility': 'Saint Anthony Hospital', 'geoPoint': {'lat': 39.70471, 'lon': -105.08137}}, {'zip': '80122', 'city': 'Littleton', 'state': 'Colorado', 'country': 'United States', 'facility': 'Littleton Adventist Hospital', 'geoPoint': {'lat': 39.61332, 'lon': -105.01665}}, {'zip': '80501', 'city': 'Longmont', 'state': 'Colorado', 'country': 'United States', 'facility': 'Longmont United Hospital', 'geoPoint': {'lat': 40.16721, 'lon': -105.10193}}, {'zip': '80501', 'city': 'Longmont', 'state': 'Colorado', 'country': 'United States', 'facility': 'Rocky Mountain Cancer Centers-Longmont', 'geoPoint': {'lat': 40.16721, 'lon': -105.10193}}, {'zip': '80138', 'city': 'Parker', 'state': 'Colorado', 'country': 'United States', 'facility': 'Parker Adventist Hospital', 'geoPoint': {'lat': 39.5186, 'lon': -104.76136}}, {'zip': '81004', 'city': 'Pueblo', 'state': 'Colorado', 'country': 'United States', 'facility': 'Saint Mary Corwin Medical Center', 'geoPoint': {'lat': 38.25445, 'lon': -104.60914}}, {'zip': '60504', 'city': 'Aurora', 'state': 'Illinois', 'country': 'United States', 'facility': 'Rush - Copley Medical Center', 'geoPoint': {'lat': 41.76058, 'lon': -88.32007}}, {'zip': '61704', 'city': 'Bloomington', 'state': 'Illinois', 'country': 'United States', 'facility': 'Illinois CancerCare-Bloomington', 'geoPoint': {'lat': 40.4842, 'lon': -88.99369}}, {'zip': '61520', 'city': 'Canton', 'state': 'Illinois', 'country': 'United States', 'facility': 'Illinois CancerCare-Canton', 'geoPoint': {'lat': 40.55809, 'lon': -90.03512}}, {'zip': '62902', 'city': 'Carbondale', 'state': 'Illinois', 'country': 'United States', 'facility': 'Memorial Hospital of Carbondale', 'geoPoint': {'lat': 37.72727, 'lon': -89.21675}}, {'zip': '62918', 'city': 'Carterville', 'state': 'Illinois', 'country': 'United States', 'facility': 'SIH Cancer Institute', 'geoPoint': {'lat': 37.76005, 'lon': -89.0773}}, {'zip': '62321', 'city': 'Carthage', 'state': 'Illinois', 'country': 'United States', 'facility': 'Illinois CancerCare-Carthage', 'geoPoint': {'lat': 40.41643, 'lon': -91.13625}}, {'zip': '62801', 'city': 'Centralia', 'state': 'Illinois', 'country': 'United States', 'facility': 'Centralia Oncology Clinic', 'geoPoint': {'lat': 38.52505, 'lon': -89.1334}}, {'zip': '61832', 'city': 'Danville', 'state': 'Illinois', 'country': 'United States', 'facility': 'Carle at The Riverfront', 'geoPoint': {'lat': 40.12448, 'lon': -87.63002}}, {'zip': '62526', 'city': 'Decatur', 'state': 'Illinois', 'country': 'United States', 'facility': 'Cancer Care Specialists of Illinois - Decatur', 'geoPoint': {'lat': 39.84031, 'lon': -88.9548}}, {'zip': '62526', 'city': 'Decatur', 'state': 'Illinois', 'country': 'United States', 'facility': 'Decatur Memorial Hospital', 'geoPoint': {'lat': 39.84031, 'lon': -88.9548}}, {'zip': '61021', 'city': 'Dixon', 'state': 'Illinois', 'country': 'United States', 'facility': 'Illinois CancerCare-Dixon', 'geoPoint': {'lat': 41.83892, 'lon': -89.47955}}, {'zip': '62401', 'city': 'Effingham', 'state': 'Illinois', 'country': 'United States', 'facility': 'Carle Physician Group-Effingham', 'geoPoint': {'lat': 39.12004, 'lon': -88.54338}}, {'zip': '62401', 'city': 'Effingham', 'state': 'Illinois', 'country': 'United States', 'facility': 'Crossroads Cancer Center', 'geoPoint': {'lat': 39.12004, 'lon': -88.54338}}, {'zip': '61530', 'city': 'Eureka', 'state': 'Illinois', 'country': 'United States', 'facility': 'Illinois CancerCare-Eureka', 'geoPoint': {'lat': 40.72143, 'lon': -89.27286}}, {'zip': '61401', 'city': 'Galesburg', 'state': 'Illinois', 'country': 'United States', 'facility': 'Illinois CancerCare-Galesburg', 'geoPoint': {'lat': 40.94782, 'lon': -90.37124}}, {'zip': '61401', 'city': 'Galesburg', 'state': 'Illinois', 'country': 'United States', 'facility': 'Western Illinois Cancer Treatment Center', 'geoPoint': {'lat': 40.94782, 'lon': -90.37124}}, {'zip': '61443', 'city': 'Kewanee', 'state': 'Illinois', 'country': 'United States', 'facility': 'Illinois CancerCare-Kewanee Clinic', 'geoPoint': {'lat': 41.24559, 'lon': -89.92483}}, {'zip': '61455', 'city': 'Macomb', 'state': 'Illinois', 'country': 'United States', 'facility': 'Illinois CancerCare-Macomb', 'geoPoint': {'lat': 40.45921, 'lon': -90.6718}}, {'zip': '61938', 'city': 'Mattoon', 'state': 'Illinois', 'country': 'United States', 'facility': 'Carle Physician Group-Mattoon/Charleston', 'geoPoint': {'lat': 39.48309, 'lon': -88.37283}}, {'zip': '62269', 'city': "O'Fallon", 'state': 'Illinois', 'country': 'United States', 'facility': "Cancer Care Center of O'Fallon", 'geoPoint': {'lat': 38.59227, 'lon': -89.91121}}, {'zip': '61350', 'city': 'Ottawa', 'state': 'Illinois', 'country': 'United States', 'facility': 'Illinois CancerCare-Ottawa Clinic', 'geoPoint': {'lat': 41.34559, 'lon': -88.84258}}, {'zip': '61554', 'city': 'Pekin', 'state': 'Illinois', 'country': 'United States', 'facility': 'Illinois CancerCare-Pekin', 'geoPoint': {'lat': 40.56754, 'lon': -89.64066}}, {'zip': '61615', 'city': 'Peoria', 'state': 'Illinois', 'country': 'United States', 'facility': 'Illinois CancerCare-Peoria', 'geoPoint': {'lat': 40.69365, 'lon': -89.58899}}, {'zip': '61636', 'city': 'Peoria', 'state': 'Illinois', 'country': 'United States', 'facility': 'Methodist Medical Center of Illinois', 'geoPoint': {'lat': 40.69365, 'lon': -89.58899}}, {'zip': '61354', 'city': 'Peru', 'state': 'Illinois', 'country': 'United States', 'facility': 'Illinois CancerCare-Peru', 'geoPoint': {'lat': 41.32753, 'lon': -89.12897}}, {'zip': '61354', 'city': 'Peru', 'state': 'Illinois', 'country': 'United States', 'facility': 'Valley Radiation Oncology', 'geoPoint': {'lat': 41.32753, 'lon': -89.12897}}, {'zip': '61356', 'city': 'Princeton', 'state': 'Illinois', 'country': 'United States', 'facility': 'Illinois CancerCare-Princeton', 'geoPoint': {'lat': 41.36809, 'lon': -89.46481}}, {'zip': '62702', 'city': 'Springfield', 'state': 'Illinois', 'country': 'United States', 'facility': 'Southern Illinois University School of Medicine', 'geoPoint': {'lat': 39.80172, 'lon': -89.64371}}, {'zip': '62702', 'city': 'Springfield', 'state': 'Illinois', 'country': 'United States', 'facility': 'Springfield Clinic', 'geoPoint': {'lat': 39.80172, 'lon': -89.64371}}, {'zip': '62781', 'city': 'Springfield', 'state': 'Illinois', 'country': 'United States', 'facility': 'Springfield Memorial Hospital', 'geoPoint': {'lat': 39.80172, 'lon': -89.64371}}, {'zip': '61801', 'city': 'Urbana', 'state': 'Illinois', 'country': 'United States', 'facility': 'Carle Cancer Center', 'geoPoint': {'lat': 40.11059, 'lon': -88.20727}}, {'zip': '61801', 'city': 'Urbana', 'state': 'Illinois', 'country': 'United States', 'facility': 'The Carle Foundation Hospital', 'geoPoint': {'lat': 40.11059, 'lon': -88.20727}}, {'zip': '61571', 'city': 'Washington', 'state': 'Illinois', 'country': 'United States', 'facility': 'Illinois CancerCare - Washington', 'geoPoint': {'lat': 40.70365, 'lon': -89.40731}}, {'zip': '60560', 'city': 'Yorkville', 'state': 'Illinois', 'country': 'United States', 'facility': 'Rush-Copley Healthcare Center', 'geoPoint': {'lat': 41.64114, 'lon': -88.44729}}, {'zip': '50010', 'city': 'Ames', 'state': 'Iowa', 'country': 'United States', 'facility': 'Mary Greeley Medical Center', 'geoPoint': {'lat': 42.03471, 'lon': -93.61994}}, {'zip': '50010', 'city': 'Ames', 'state': 'Iowa', 'country': 'United States', 'facility': 'McFarland Clinic - Ames', 'geoPoint': {'lat': 42.03471, 'lon': -93.61994}}, {'zip': '50036', 'city': 'Boone', 'state': 'Iowa', 'country': 'United States', 'facility': 'McFarland Clinic - Boone', 'geoPoint': {'lat': 42.0597, 'lon': -93.88023}}, {'zip': '51401', 'city': 'Carroll', 'state': 'Iowa', 'country': 'United States', 'facility': 'Saint Anthony Regional Hospital', 'geoPoint': {'lat': 42.06582, 'lon': -94.86693}}, {'zip': '50325', 'city': 'Clive', 'state': 'Iowa', 'country': 'United States', 'facility': 'Mercy Cancer Center-West Lakes', 'geoPoint': {'lat': 41.60304, 'lon': -93.72411}}, {'zip': '50325', 'city': 'Clive', 'state': 'Iowa', 'country': 'United States', 'facility': 'Mission Cancer and Blood - West Des Moines', 'geoPoint': {'lat': 41.60304, 'lon': -93.72411}}, {'zip': '51503', 'city': 'Council Bluffs', 'state': 'Iowa', 'country': 'United States', 'facility': 'Alegent Health Mercy Hospital', 'geoPoint': {'lat': 41.26194, 'lon': -95.86083}}, {'zip': '50801', 'city': 'Creston', 'state': 'Iowa', 'country': 'United States', 'facility': 'Greater Regional Medical Center', 'geoPoint': {'lat': 41.0586, 'lon': -94.36135}}, {'zip': '50309', 'city': 'Des Moines', 'state': 'Iowa', 'country': 'United States', 'facility': 'Iowa Methodist Medical Center', 'geoPoint': {'lat': 41.60054, 'lon': -93.60911}}, {'zip': '50309', 'city': 'Des Moines', 'state': 'Iowa', 'country': 'United States', 'facility': 'Mission Cancer and Blood - Des Moines', 'geoPoint': {'lat': 41.60054, 'lon': -93.60911}}, {'zip': '50314', 'city': 'Des Moines', 'state': 'Iowa', 'country': 'United States', 'facility': 'Broadlawns Medical Center', 'geoPoint': {'lat': 41.60054, 'lon': -93.60911}}, {'zip': '50314', 'city': 'Des Moines', 'state': 'Iowa', 'country': 'United States', 'facility': 'Mercy Medical Center - Des Moines', 'geoPoint': {'lat': 41.60054, 'lon': -93.60911}}, {'zip': '50314', 'city': 'Des Moines', 'state': 'Iowa', 'country': 'United States', 'facility': 'Mission Cancer and Blood - Laurel', 'geoPoint': {'lat': 41.60054, 'lon': -93.60911}}, {'zip': '50316', 'city': 'Des Moines', 'state': 'Iowa', 'country': 'United States', 'facility': 'Iowa Lutheran Hospital', 'geoPoint': {'lat': 41.60054, 'lon': -93.60911}}, {'zip': '50501', 'city': 'Fort Dodge', 'state': 'Iowa', 'country': 'United States', 'facility': 'McFarland Clinic - Trinity Cancer Center', 'geoPoint': {'lat': 42.49747, 'lon': -94.16802}}, {'zip': '50501', 'city': 'Fort Dodge', 'state': 'Iowa', 'country': 'United States', 'facility': 'Trinity Regional Medical Center', 'geoPoint': {'lat': 42.49747, 'lon': -94.16802}}, {'zip': '50129', 'city': 'Jefferson', 'state': 'Iowa', 'country': 'United States', 'facility': 'McFarland Clinic - Jefferson', 'geoPoint': {'lat': 42.01526, 'lon': -94.37747}}, {'zip': '50158', 'city': 'Marshalltown', 'state': 'Iowa', 'country': 'United States', 'facility': 'McFarland Clinic - Marshalltown', 'geoPoint': {'lat': 42.04943, 'lon': -92.90798}}, {'zip': '50266-7700', 'city': 'West Des Moines', 'state': 'Iowa', 'country': 'United States', 'facility': 'Methodist West Hospital', 'geoPoint': {'lat': 41.57721, 'lon': -93.71133}}, {'zip': '50266', 'city': 'West Des Moines', 'state': 'Iowa', 'country': 'United States', 'facility': 'Mercy Medical Center-West Lakes', 'geoPoint': {'lat': 41.57721, 'lon': -93.71133}}, {'zip': '67208', 'city': 'Wichita', 'state': 'Kansas', 'country': 'United States', 'facility': 'Cancer Center of Kansas-Wichita Medical Arts Tower', 'geoPoint': {'lat': 37.69224, 'lon': -97.33754}}, {'zip': '67214', 'city': 'Wichita', 'state': 'Kansas', 'country': 'United States', 'facility': 'Ascension Via Christi Hospitals Wichita', 'geoPoint': {'lat': 37.69224, 'lon': -97.33754}}, {'zip': '67214', 'city': 'Wichita', 'state': 'Kansas', 'country': 'United States', 'facility': 'Cancer Center of Kansas - Wichita', 'geoPoint': {'lat': 37.69224, 'lon': -97.33754}}, {'zip': '40004', 'city': 'Bardstown', 'state': 'Kentucky', 'country': 'United States', 'facility': 'Flaget Memorial Hospital', 'geoPoint': {'lat': 37.80923, 'lon': -85.4669}}, {'zip': '40701', 'city': 'Corbin', 'state': 'Kentucky', 'country': 'United States', 'facility': 'Commonwealth Cancer Center-Corbin', 'geoPoint': {'lat': 36.9487, 'lon': -84.09688}}, {'zip': '40504', 'city': 'Lexington', 'state': 'Kentucky', 'country': 'United States', 'facility': 'Saint Joseph Radiation Oncology Resource Center', 'geoPoint': {'lat': 37.98869, 'lon': -84.47772}}, {'zip': '40509', 'city': 'Lexington', 'state': 'Kentucky', 'country': 'United States', 'facility': 'Saint Joseph Hospital East', 'geoPoint': {'lat': 37.98869, 'lon': -84.47772}}, {'zip': '40741', 'city': 'London', 'state': 'Kentucky', 'country': 'United States', 'facility': 'Saint Joseph London', 'geoPoint': {'lat': 37.12898, 'lon': -84.08326}}, {'zip': '40202', 'city': 'Louisville', 'state': 'Kentucky', 'country': 'United States', 'facility': 'Jewish Hospital', 'geoPoint': {'lat': 38.25424, 'lon': -85.75941}}, {'zip': '40215', 'city': 'Louisville', 'state': 'Kentucky', 'country': 'United States', 'facility': 'Saints Mary and Elizabeth Hospital', 'geoPoint': {'lat': 38.25424, 'lon': -85.75941}}, {'zip': '40245', 'city': 'Louisville', 'state': 'Kentucky', 'country': 'United States', 'facility': 'UofL Health Medical Center Northeast', 'geoPoint': {'lat': 38.25424, 'lon': -85.75941}}, {'zip': '40165', 'city': 'Shepherdsville', 'state': 'Kentucky', 'country': 'United States', 'facility': 'Jewish Hospital Medical Center South', 'geoPoint': {'lat': 37.9884, 'lon': -85.71579}}, {'zip': '02111', 'city': 'Boston', 'state': 'Massachusetts', 'country': 'United States', 'facility': 'Tufts Medical Center', 'geoPoint': {'lat': 42.35843, 'lon': -71.05977}}, {'zip': '48106', 'city': 'Ann Arbor', 'state': 'Michigan', 'country': 'United States', 'facility': 'Trinity Health Saint Joseph Mercy Hospital Ann Arbor', 'geoPoint': {'lat': 42.27756, 'lon': -83.74088}}, {'zip': '48109', 'city': 'Ann Arbor', 'state': 'Michigan', 'country': 'United States', 'facility': 'University of Michigan Comprehensive Cancer Center', 'geoPoint': {'lat': 42.27756, 'lon': -83.74088}}, {'zip': '49017', 'city': 'Battle Creek', 'state': 'Michigan', 'country': 'United States', 'facility': 'Bronson Battle Creek', 'geoPoint': {'lat': 42.3173, 'lon': -85.17816}}, {'zip': '48114', 'city': 'Brighton', 'state': 'Michigan', 'country': 'United States', 'facility': 'Trinity Health IHA Medical Group Hematology Oncology - Brighton', 'geoPoint': {'lat': 42.52948, 'lon': -83.78022}}, {'zip': '48114', 'city': 'Brighton', 'state': 'Michigan', 'country': 'United States', 'facility': 'Trinity Health Medical Center - Brighton', 'geoPoint': {'lat': 42.52948, 'lon': -83.78022}}, {'zip': '48188', 'city': 'Canton', 'state': 'Michigan', 'country': 'United States', 'facility': 'Trinity Health IHA Medical Group Hematology Oncology - Canton', 'geoPoint': {'lat': 42.30865, 'lon': -83.48216}}, {'zip': '48188', 'city': 'Canton', 'state': 'Michigan', 'country': 'United States', 'facility': 'Trinity Health Medical Center - Canton', 'geoPoint': {'lat': 42.30865, 'lon': -83.48216}}, {'zip': '48118', 'city': 'Chelsea', 'state': 'Michigan', 'country': 'United States', 'facility': 'Chelsea Hospital', 'geoPoint': {'lat': 42.31807, 'lon': -84.02181}}, {'zip': '48118', 'city': 'Chelsea', 'state': 'Michigan', 'country': 'United States', 'facility': 'Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital', 'geoPoint': {'lat': 42.31807, 'lon': -84.02181}}, {'zip': '48236', 'city': 'Detroit', 'state': 'Michigan', 'country': 'United States', 'facility': 'Henry Ford Health Saint John Hospital', 'geoPoint': {'lat': 42.33143, 'lon': -83.04575}}, {'zip': '48054', 'city': 'East China Township', 'state': 'Michigan', 'country': 'United States', 'facility': 'Henry Ford River District Hospital'}, {'zip': '48503', 'city': 'Flint', 'state': 'Michigan', 'country': 'United States', 'facility': 'Cancer Hematology Centers - Flint', 'geoPoint': {'lat': 43.01253, 'lon': -83.68746}}, {'zip': '48503', 'city': 'Flint', 'state': 'Michigan', 'country': 'United States', 'facility': 'Genesee Hematology Oncology PC', 'geoPoint': {'lat': 43.01253, 'lon': -83.68746}}, {'zip': '48503', 'city': 'Flint', 'state': 'Michigan', 'country': 'United States', 'facility': 'Genesys Hurley Cancer Institute', 'geoPoint': {'lat': 43.01253, 'lon': -83.68746}}, {'zip': '49503', 'city': 'Grand Rapids', 'state': 'Michigan', 'country': 'United States', 'facility': 'Corewell Health Grand Rapids Hospitals - Butterworth Hospital', 'geoPoint': {'lat': 42.96336, 'lon': -85.66809}}, {'zip': '49503', 'city': 'Grand Rapids', 'state': 'Michigan', 'country': 'United States', 'facility': 'Trinity Health Grand Rapids Hospital', 'geoPoint': {'lat': 42.96336, 'lon': -85.66809}}, {'zip': '48236', 'city': 'Grosse Pointe Woods', 'state': 'Michigan', 'country': 'United States', 'facility': 'Henry Ford Saint John Hospital - Academic', 'geoPoint': {'lat': 42.44365, 'lon': -82.90686}}, {'zip': '48236', 'city': 'Grosse Pointe Woods', 'state': 'Michigan', 'country': 'United States', 'facility': 'Henry Ford Saint John Hospital - Van Elslander', 'geoPoint': {'lat': 42.44365, 'lon': -82.90686}}, {'zip': '49007', 'city': 'Kalamazoo', 'state': 'Michigan', 'country': 'United States', 'facility': 'Bronson Methodist Hospital', 'geoPoint': {'lat': 42.29171, 'lon': -85.58723}}, {'zip': '49007', 'city': 'Kalamazoo', 'state': 'Michigan', 'country': 'United States', 'facility': 'West Michigan Cancer Center', 'geoPoint': {'lat': 42.29171, 'lon': -85.58723}}, {'zip': '49009', 'city': 'Kalamazoo', 'state': 'Michigan', 'country': 'United States', 'facility': 'Ascension Borgess Cancer Center', 'geoPoint': {'lat': 42.29171, 'lon': -85.58723}}, {'zip': '48154', 'city': 'Livonia', 'state': 'Michigan', 'country': 'United States', 'facility': 'Trinity Health Saint Mary Mercy Livonia Hospital', 'geoPoint': {'lat': 42.36837, 'lon': -83.35271}}, {'zip': '48044', 'city': 'Macomb', 'state': 'Michigan', 'country': 'United States', 'facility': 'Henry Ford Saint John Hospital - Macomb Medical', 'geoPoint': {'lat': 42.70087, 'lon': -82.95909}}, {'zip': '49444', 'city': 'Muskegon', 'state': 'Michigan', 'country': 'United States', 'facility': 'Trinity Health Muskegon Hospital', 'geoPoint': {'lat': 43.23418, 'lon': -86.24839}}, {'zip': '49444', 'city': 'Norton Shores', 'state': 'Michigan', 'country': 'United States', 'facility': 'Cancer and Hematology Centers of Western Michigan - Norton Shores', 'geoPoint': {'lat': 43.1689, 'lon': -86.26395}}, {'zip': '49677', 'city': 'Reed City', 'state': 'Michigan', 'country': 'United States', 'facility': 'Corewell Health Reed City Hospital', 'geoPoint': {'lat': 43.87502, 'lon': -85.51005}}, {'zip': '49085', 'city': 'Saint Joseph', 'state': 'Michigan', 'country': 'United States', 'facility': 'Corewell Health Lakeland Hospitals - Marie Yeager Cancer Center', 'geoPoint': {'lat': 42.10976, 'lon': -86.48002}}, {'zip': '48312', 'city': 'Sterling Heights', 'state': 'Michigan', 'country': 'United States', 'facility': 'Bhadresh Nayak MD PC-Sterling Heights', 'geoPoint': {'lat': 42.58031, 'lon': -83.0302}}, {'zip': '49684', 'city': 'Traverse City', 'state': 'Michigan', 'country': 'United States', 'facility': 'Munson Medical Center', 'geoPoint': {'lat': 44.76306, 'lon': -85.62063}}, {'zip': '48093', 'city': 'Warren', 'state': 'Michigan', 'country': 'United States', 'facility': 'Henry Ford Health Warren Hospital', 'geoPoint': {'lat': 42.49044, 'lon': -83.01304}}, {'zip': '48093', 'city': 'Warren', 'state': 'Michigan', 'country': 'United States', 'facility': 'Henry Ford Warren Hospital - GLCMS', 'geoPoint': {'lat': 42.49044, 'lon': -83.01304}}, {'zip': '48093', 'city': 'Warren', 'state': 'Michigan', 'country': 'United States', 'facility': 'Macomb Hematology Oncology PC', 'geoPoint': {'lat': 42.49044, 'lon': -83.01304}}, {'zip': '49519', 'city': 'Wyoming', 'state': 'Michigan', 'country': 'United States', 'facility': 'University of Michigan Health - West', 'geoPoint': {'lat': 42.91336, 'lon': -85.70531}}, {'zip': '48106', 'city': 'Ypsilanti', 'state': 'Michigan', 'country': 'United States', 'facility': 'Huron Gastroenterology PC', 'geoPoint': {'lat': 42.24115, 'lon': -83.61299}}, {'zip': '48197', 'city': 'Ypsilanti', 'state': 'Michigan', 'country': 'United States', 'facility': 'Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus', 'geoPoint': {'lat': 42.24115, 'lon': -83.61299}}, {'zip': '56601', 'city': 'Bemidji', 'state': 'Minnesota', 'country': 'United States', 'facility': 'Sanford Joe Lueken Cancer Center', 'geoPoint': {'lat': 47.47356, 'lon': -94.88028}}, {'zip': '55337', 'city': 'Burnsville', 'state': 'Minnesota', 'country': 'United States', 'facility': 'Fairview Ridges Hospital', 'geoPoint': {'lat': 44.76774, 'lon': -93.27772}}, {'zip': '55337', 'city': 'Burnsville', 'state': 'Minnesota', 'country': 'United States', 'facility': 'Minnesota Oncology - Burnsville', 'geoPoint': {'lat': 44.76774, 'lon': -93.27772}}, {'zip': '55008', 'city': 'Cambridge', 'state': 'Minnesota', 'country': 'United States', 'facility': 'Cambridge Medical Center', 'geoPoint': {'lat': 45.57274, 'lon': -93.22439}}, {'zip': '55433', 'city': 'Coon Rapids', 'state': 'Minnesota', 'country': 'United States', 'facility': 'Mercy Hospital', 'geoPoint': {'lat': 45.11997, 'lon': -93.28773}}, {'zip': '55435', 'city': 'Edina', 'state': 'Minnesota', 'country': 'United States', 'facility': 'Fairview Southdale Hospital', 'geoPoint': {'lat': 44.88969, 'lon': -93.34995}}, {'zip': '55432', 'city': 'Fridley', 'state': 'Minnesota', 'country': 'United States', 'facility': 'Unity Hospital', 'geoPoint': {'lat': 45.08608, 'lon': -93.26328}}, {'zip': '55369', 'city': 'Maple Grove', 'state': 'Minnesota', 'country': 'United States', 'facility': 'Fairview Clinics and Surgery Center Maple Grove', 'geoPoint': {'lat': 45.07246, 'lon': -93.45579}}, {'zip': '55109', 'city': 'Maplewood', 'state': 'Minnesota', 'country': 'United States', 'facility': 'Minnesota Oncology Hematology PA-Maplewood', 'geoPoint': {'lat': 44.95302, 'lon': -92.99522}}, {'zip': '55109', 'city': 'Maplewood', 'state': 'Minnesota', 'country': 'United States', 'facility': "Saint John's Hospital - Healtheast", 'geoPoint': {'lat': 44.95302, 'lon': -92.99522}}, {'zip': '55407', 'city': 'Minneapolis', 'state': 'Minnesota', 'country': 'United States', 'facility': 'Abbott-Northwestern Hospital', 'geoPoint': {'lat': 44.97997, 'lon': -93.26384}}, {'zip': '55415', 'city': 'Minneapolis', 'state': 'Minnesota', 'country': 'United States', 'facility': 'Hennepin County Medical Center', 'geoPoint': {'lat': 44.97997, 'lon': -93.26384}}, {'zip': '55454', 'city': 'Minneapolis', 'state': 'Minnesota', 'country': 'United States', 'facility': 'Health Partners Inc', 'geoPoint': {'lat': 44.97997, 'lon': -93.26384}}, {'zip': '55362', 'city': 'Monticello', 'state': 'Minnesota', 'country': 'United States', 'facility': 'Monticello Cancer Center', 'geoPoint': {'lat': 45.30552, 'lon': -93.79414}}, {'zip': '56073', 'city': 'New Ulm', 'state': 'Minnesota', 'country': 'United States', 'facility': 'New Ulm Medical Center', 'geoPoint': {'lat': 44.31246, 'lon': -94.46053}}, {'zip': '55371', 'city': 'Princeton', 'state': 'Minnesota', 'country': 'United States', 'facility': 'Fairview Northland Medical Center', 'geoPoint': {'lat': 45.56997, 'lon': -93.58163}}, {'zip': '55422', 'city': 'Robbinsdale', 'state': 'Minnesota', 'country': 'United States', 'facility': 'North Memorial Medical Health Center', 'geoPoint': {'lat': 45.03219, 'lon': -93.33856}}, {'zip': '55905', 'city': 'Rochester', 'state': 'Minnesota', 'country': 'United States', 'facility': 'Mayo Clinic in Rochester', 'geoPoint': {'lat': 44.02163, 'lon': -92.4699}}, {'zip': '55416', 'city': 'Saint Louis Park', 'state': 'Minnesota', 'country': 'United States', 'facility': 'Park Nicollet Clinic - Saint Louis Park', 'geoPoint': {'lat': 44.9483, 'lon': -93.34801}}, {'zip': '55101', 'city': 'Saint Paul', 'state': 'Minnesota', 'country': 'United States', 'facility': 'Regions Hospital', 'geoPoint': {'lat': 44.94441, 'lon': -93.09327}}, {'zip': '55102', 'city': 'Saint Paul', 'state': 'Minnesota', 'country': 'United States', 'facility': 'United Hospital', 'geoPoint': {'lat': 44.94441, 'lon': -93.09327}}, {'zip': '55379', 'city': 'Shakopee', 'state': 'Minnesota', 'country': 'United States', 'facility': 'Saint Francis Regional Medical Center', 'geoPoint': {'lat': 44.79802, 'lon': -93.5269}}, {'zip': '55082', 'city': 'Stillwater', 'state': 'Minnesota', 'country': 'United States', 'facility': 'Lakeview Hospital', 'geoPoint': {'lat': 45.05636, 'lon': -92.80604}}, {'zip': '55387', 'city': 'Waconia', 'state': 'Minnesota', 'country': 'United States', 'facility': 'Ridgeview Medical Center', 'geoPoint': {'lat': 44.8508, 'lon': -93.78691}}, {'zip': '56201', 'city': 'Willmar', 'state': 'Minnesota', 'country': 'United States', 'facility': 'Rice Memorial Hospital', 'geoPoint': {'lat': 45.12191, 'lon': -95.04334}}, {'zip': '55125', 'city': 'Woodbury', 'state': 'Minnesota', 'country': 'United States', 'facility': 'Minnesota Oncology Hematology PA-Woodbury', 'geoPoint': {'lat': 44.92386, 'lon': -92.95938}}, {'zip': '55092', 'city': 'Wyoming', 'state': 'Minnesota', 'country': 'United States', 'facility': 'Fairview Lakes Medical Center', 'geoPoint': {'lat': 45.33636, 'lon': -92.99716}}, {'zip': '63703', 'city': 'Cape Girardeau', 'state': 'Missouri', 'country': 'United States', 'facility': 'Saint Francis Medical Center', 'geoPoint': {'lat': 37.30588, 'lon': -89.51815}}, {'zip': '63703', 'city': 'Cape Girardeau', 'state': 'Missouri', 'country': 'United States', 'facility': 'Southeast Cancer Center', 'geoPoint': {'lat': 37.30588, 'lon': -89.51815}}, {'zip': '63640', 'city': 'Farmington', 'state': 'Missouri', 'country': 'United States', 'facility': 'Parkland Health Center - Farmington', 'geoPoint': {'lat': 37.78088, 'lon': -90.42179}}, {'zip': '65109', 'city': 'Jefferson City', 'state': 'Missouri', 'country': 'United States', 'facility': 'MU Health Care Goldschmidt Cancer Center', 'geoPoint': {'lat': 38.5767, 'lon': -92.17352}}, {'zip': '63670', 'city': 'Sainte Genevieve', 'state': 'Missouri', 'country': 'United States', 'facility': 'Sainte Genevieve County Memorial Hospital', 'geoPoint': {'lat': 37.98144, 'lon': -90.04178}}, {'zip': '63131', 'city': 'St Louis', 'state': 'Missouri', 'country': 'United States', 'facility': 'Missouri Baptist Medical Center', 'geoPoint': {'lat': 38.62727, 'lon': -90.19789}}, {'zip': '63141', 'city': 'St Louis', 'state': 'Missouri', 'country': 'United States', 'facility': 'Mercy Hospital Saint Louis', 'geoPoint': {'lat': 38.62727, 'lon': -90.19789}}, {'zip': '63080', 'city': 'Sullivan', 'state': 'Missouri', 'country': 'United States', 'facility': 'Missouri Baptist Sullivan Hospital', 'geoPoint': {'lat': 38.2081, 'lon': -91.16042}}, {'zip': '63127', 'city': 'Sunset Hills', 'state': 'Missouri', 'country': 'United States', 'facility': 'BJC Outpatient Center at Sunset Hills', 'geoPoint': {'lat': 38.53894, 'lon': -90.40734}}, {'zip': '68803', 'city': 'Grand Island', 'state': 'Nebraska', 'country': 'United States', 'facility': 'Nebraska Cancer Specialists/Oncology Hematology West PC', 'geoPoint': {'lat': 40.92501, 'lon': -98.34201}}, {'zip': '68847', 'city': 'Kearney', 'state': 'Nebraska', 'country': 'United States', 'facility': 'CHI Health Good Samaritan', 'geoPoint': {'lat': 40.69946, 'lon': -99.08148}}, {'zip': '68510', 'city': 'Lincoln', 'state': 'Nebraska', 'country': 'United States', 'facility': 'Saint Elizabeth Regional Medical Center', 'geoPoint': {'lat': 40.8, 'lon': -96.66696}}, {'zip': '68122', 'city': 'Omaha', 'state': 'Nebraska', 'country': 'United States', 'facility': 'Alegent Health Immanuel Medical Center', 'geoPoint': {'lat': 41.25626, 'lon': -95.94043}}, {'zip': '68124', 'city': 'Omaha', 'state': 'Nebraska', 'country': 'United States', 'facility': 'Alegent Health Bergan Mercy Medical Center', 'geoPoint': {'lat': 41.25626, 'lon': -95.94043}}, {'zip': '68130', 'city': 'Omaha', 'state': 'Nebraska', 'country': 'United States', 'facility': 'Alegent Health Lakeside Hospital', 'geoPoint': {'lat': 41.25626, 'lon': -95.94043}}, {'zip': '68131', 'city': 'Omaha', 'state': 'Nebraska', 'country': 'United States', 'facility': 'Creighton University Medical Center', 'geoPoint': {'lat': 41.25626, 'lon': -95.94043}}, {'zip': '68046', 'city': 'Papillion', 'state': 'Nebraska', 'country': 'United States', 'facility': 'Midlands Community Hospital', 'geoPoint': {'lat': 41.15444, 'lon': -96.04224}}, {'zip': '58501', 'city': 'Bismarck', 'state': 'North Dakota', 'country': 'United States', 'facility': 'Sanford Bismarck Medical Center', 'geoPoint': {'lat': 46.80833, 'lon': -100.78374}}, {'zip': '58122', 'city': 'Fargo', 'state': 'North Dakota', 'country': 'United States', 'facility': 'Sanford Broadway Medical Center', 'geoPoint': {'lat': 46.87719, 'lon': -96.7898}}, {'zip': '58122', 'city': 'Fargo', 'state': 'North Dakota', 'country': 'United States', 'facility': 'Sanford Roger Maris Cancer Center', 'geoPoint': {'lat': 46.87719, 'lon': -96.7898}}, {'zip': '45714', 'city': 'Belpre', 'state': 'Ohio', 'country': 'United States', 'facility': 'Strecker Cancer Center-Belpre', 'geoPoint': {'lat': 39.27396, 'lon': -81.5729}}, {'zip': '45459', 'city': 'Centerville', 'state': 'Ohio', 'country': 'United States', 'facility': 'Miami Valley Hospital South', 'geoPoint': {'lat': 39.62839, 'lon': -84.15938}}, {'zip': '45601', 'city': 'Chillicothe', 'state': 'Ohio', 'country': 'United States', 'facility': 'Adena Regional Medical Center', 'geoPoint': {'lat': 39.33312, 'lon': -82.9824}}, {'zip': '45220', 'city': 'Cincinnati', 'state': 'Ohio', 'country': 'United States', 'facility': 'Good Samaritan Hospital - Cincinnati', 'geoPoint': {'lat': 39.12711, 'lon': -84.51439}}, {'zip': '45242', 'city': 'Cincinnati', 'state': 'Ohio', 'country': 'United States', 'facility': 'Bethesda North Hospital', 'geoPoint': {'lat': 39.12711, 'lon': -84.51439}}, {'zip': '45247', 'city': 'Cincinnati', 'state': 'Ohio', 'country': 'United States', 'facility': 'TriHealth Cancer Institute-Westside', 'geoPoint': {'lat': 39.12711, 'lon': -84.51439}}, {'zip': '45255', 'city': 'Cincinnati', 'state': 'Ohio', 'country': 'United States', 'facility': 'TriHealth Cancer Institute-Anderson', 'geoPoint': {'lat': 39.12711, 'lon': -84.51439}}, {'zip': '43213', 'city': 'Columbus', 'state': 'Ohio', 'country': 'United States', 'facility': 'Mount Carmel East Hospital', 'geoPoint': {'lat': 39.96118, 'lon': -82.99879}}, {'zip': '43214', 'city': 'Columbus', 'state': 'Ohio', 'country': 'United States', 'facility': 'Columbus Oncology and Hematology Associates Inc', 'geoPoint': {'lat': 39.96118, 'lon': -82.99879}}, {'zip': '43214', 'city': 'Columbus', 'state': 'Ohio', 'country': 'United States', 'facility': 'Riverside Methodist Hospital', 'geoPoint': {'lat': 39.96118, 'lon': -82.99879}}, {'zip': '43215', 'city': 'Columbus', 'state': 'Ohio', 'country': 'United States', 'facility': 'Grant Medical Center', 'geoPoint': {'lat': 39.96118, 'lon': -82.99879}}, {'zip': '43219', 'city': 'Columbus', 'state': 'Ohio', 'country': 'United States', 'facility': 'The Mark H Zangmeister Center', 'geoPoint': {'lat': 39.96118, 'lon': -82.99879}}, {'zip': '43222', 'city': 'Columbus', 'state': 'Ohio', 'country': 'United States', 'facility': 'Mount Carmel Health Center West', 'geoPoint': {'lat': 39.96118, 'lon': -82.99879}}, {'zip': '43228', 'city': 'Columbus', 'state': 'Ohio', 'country': 'United States', 'facility': 'Doctors Hospital', 'geoPoint': {'lat': 39.96118, 'lon': -82.99879}}, {'zip': '45409', 'city': 'Dayton', 'state': 'Ohio', 'country': 'United States', 'facility': 'Miami Valley Hospital', 'geoPoint': {'lat': 39.75895, 'lon': -84.19161}}, {'zip': '45415', 'city': 'Dayton', 'state': 'Ohio', 'country': 'United States', 'facility': 'Miami Valley Hospital North', 'geoPoint': {'lat': 39.75895, 'lon': -84.19161}}, {'zip': '43015', 'city': 'Delaware', 'state': 'Ohio', 'country': 'United States', 'facility': 'Delaware Health Center-Grady Cancer Center', 'geoPoint': {'lat': 40.29867, 'lon': -83.06797}}, {'zip': '43015', 'city': 'Delaware', 'state': 'Ohio', 'country': 'United States', 'facility': 'Grady Memorial Hospital', 'geoPoint': {'lat': 40.29867, 'lon': -83.06797}}, {'zip': '43016', 'city': 'Dublin', 'state': 'Ohio', 'country': 'United States', 'facility': 'Dublin Methodist Hospital', 'geoPoint': {'lat': 40.09923, 'lon': -83.11408}}, {'zip': '45005-1066', 'city': 'Franklin', 'state': 'Ohio', 'country': 'United States', 'facility': 'Atrium Medical Center-Middletown Regional Hospital', 'geoPoint': {'lat': 39.55895, 'lon': -84.30411}}, {'zip': '43230', 'city': 'Gahanna', 'state': 'Ohio', 'country': 'United States', 'facility': 'Central Ohio Breast and Endocrine Surgery', 'geoPoint': {'lat': 40.01923, 'lon': -82.87934}}, {'zip': '43123', 'city': 'Grove City', 'state': 'Ohio', 'country': 'United States', 'facility': 'Mount Carmel Grove City Hospital', 'geoPoint': {'lat': 39.88145, 'lon': -83.09296}}, {'zip': '43130', 'city': 'Lancaster', 'state': 'Ohio', 'country': 'United States', 'facility': 'Fairfield Medical Center', 'geoPoint': {'lat': 39.71368, 'lon': -82.59933}}, {'zip': '45801', 'city': 'Lima', 'state': 'Ohio', 'country': 'United States', 'facility': "Saint Rita's Medical Center", 'geoPoint': {'lat': 40.74255, 'lon': -84.10523}}, {'zip': '44903', 'city': 'Mansfield', 'state': 'Ohio', 'country': 'United States', 'facility': 'OhioHealth Mansfield Hospital', 'geoPoint': {'lat': 40.75839, 'lon': -82.51545}}, {'zip': '45750', 'city': 'Marietta', 'state': 'Ohio', 'country': 'United States', 'facility': 'Marietta Memorial Hospital', 'geoPoint': {'lat': 39.41535, 'lon': -81.45484}}, {'zip': '43302', 'city': 'Marion', 'state': 'Ohio', 'country': 'United States', 'facility': 'OhioHealth Marion General Hospital', 'geoPoint': {'lat': 40.58867, 'lon': -83.12852}}, {'zip': '43050', 'city': 'Mount Vernon', 'state': 'Ohio', 'country': 'United States', 'facility': 'Knox Community Hospital', 'geoPoint': {'lat': 40.3934, 'lon': -82.48572}}, {'zip': '43055', 'city': 'Newark', 'state': 'Ohio', 'country': 'United States', 'facility': 'Licking Memorial Hospital', 'geoPoint': {'lat': 40.05812, 'lon': -82.40126}}, {'zip': '43055', 'city': 'Newark', 'state': 'Ohio', 'country': 'United States', 'facility': 'Newark Radiation Oncology', 'geoPoint': {'lat': 40.05812, 'lon': -82.40126}}, {'zip': '43551', 'city': 'Perrysburg', 'state': 'Ohio', 'country': 'United States', 'facility': 'Mercy Health - Perrysburg Hospital', 'geoPoint': {'lat': 41.557, 'lon': -83.62716}}, {'zip': '45662', 'city': 'Portsmouth', 'state': 'Ohio', 'country': 'United States', 'facility': 'Southern Ohio Medical Center', 'geoPoint': {'lat': 38.73174, 'lon': -82.99767}}, {'zip': '43608', 'city': 'Toledo', 'state': 'Ohio', 'country': 'United States', 'facility': 'Mercy Health - Saint Vincent Hospital', 'geoPoint': {'lat': 41.66394, 'lon': -83.55521}}, {'zip': '43623', 'city': 'Toledo', 'state': 'Ohio', 'country': 'United States', 'facility': 'Mercy Health - Saint Anne Hospital', 'geoPoint': {'lat': 41.66394, 'lon': -83.55521}}, {'zip': '45373', 'city': 'Troy', 'state': 'Ohio', 'country': 'United States', 'facility': 'Upper Valley Medical Center', 'geoPoint': {'lat': 40.0395, 'lon': -84.20328}}, {'zip': '43081', 'city': 'Westerville', 'state': 'Ohio', 'country': 'United States', 'facility': "Saint Ann's Hospital", 'geoPoint': {'lat': 40.12617, 'lon': -82.92907}}, {'zip': '43701', 'city': 'Zanesville', 'state': 'Ohio', 'country': 'United States', 'facility': 'Genesis Healthcare System Cancer Care Center', 'geoPoint': {'lat': 39.94035, 'lon': -82.01319}}, {'zip': '73104', 'city': 'Oklahoma City', 'state': 'Oklahoma', 'country': 'United States', 'facility': 'University of Oklahoma Health Sciences Center', 'geoPoint': {'lat': 35.46756, 'lon': -97.51643}}, {'zip': '74146', 'city': 'Tulsa', 'state': 'Oklahoma', 'country': 'United States', 'facility': 'Oklahoma Cancer Specialists and Research Institute-Tulsa', 'geoPoint': {'lat': 36.15398, 'lon': -95.99277}}, {'zip': '17033-0850', 'city': 'Hershey', 'state': 'Pennsylvania', 'country': 'United States', 'facility': 'Penn State Milton S Hershey Medical Center', 'geoPoint': {'lat': 40.28592, 'lon': -76.65025}}, {'zip': '29440', 'city': 'Georgetown', 'state': 'South Carolina', 'country': 'United States', 'facility': 'Tidelands Georgetown Memorial Hospital', 'geoPoint': {'lat': 33.37683, 'lon': -79.2945}}, {'zip': '57104', 'city': 'Sioux Falls', 'state': 'South Dakota', 'country': 'United States', 'facility': 'Sanford Cancer Center Oncology Clinic', 'geoPoint': {'lat': 43.54369, 'lon': -96.72796}}, {'zip': '57117-5134', 'city': 'Sioux Falls', 'state': 'South Dakota', 'country': 'United States', 'facility': 'Sanford USD Medical Center - Sioux Falls', 'geoPoint': {'lat': 43.54369, 'lon': -96.72796}}, {'zip': '77802', 'city': 'Bryan', 'state': 'Texas', 'country': 'United States', 'facility': 'Saint Joseph Regional Cancer Center', 'geoPoint': {'lat': 30.67436, 'lon': -96.36996}}, {'zip': '98166', 'city': 'Burien', 'state': 'Washington', 'country': 'United States', 'facility': 'Highline Medical Center-Main Campus', 'geoPoint': {'lat': 47.47038, 'lon': -122.34679}}, {'zip': '98022', 'city': 'Enumclaw', 'state': 'Washington', 'country': 'United States', 'facility': 'Saint Elizabeth Hospital', 'geoPoint': {'lat': 47.20427, 'lon': -121.9915}}, {'zip': '98003', 'city': 'Federal Way', 'state': 'Washington', 'country': 'United States', 'facility': 'Saint Francis Hospital', 'geoPoint': {'lat': 47.32232, 'lon': -122.31262}}, {'zip': '98499', 'city': 'Lakewood', 'state': 'Washington', 'country': 'United States', 'facility': 'Saint Clare Hospital', 'geoPoint': {'lat': 47.17176, 'lon': -122.51846}}, {'zip': '98383', 'city': 'Silverdale', 'state': 'Washington', 'country': 'United States', 'facility': 'Saint Michael Cancer Center', 'geoPoint': {'lat': 47.64454, 'lon': -122.69487}}, {'zip': '98405', 'city': 'Tacoma', 'state': 'Washington', 'country': 'United States', 'facility': 'Franciscan Research Center-Northwest Medical Plaza', 'geoPoint': {'lat': 47.25288, 'lon': -122.44429}}, {'zip': '54911', 'city': 'Appleton', 'state': 'Wisconsin', 'country': 'United States', 'facility': 'ThedaCare Regional Cancer Center', 'geoPoint': {'lat': 44.26193, 'lon': -88.41538}}, {'zip': '53149', 'city': 'Mukwonago', 'state': 'Wisconsin', 'country': 'United States', 'facility': 'ProHealth D N Greenwald Center', 'geoPoint': {'lat': 42.86668, 'lon': -88.33343}}, {'zip': '54017', 'city': 'New Richmond', 'state': 'Wisconsin', 'country': 'United States', 'facility': 'Cancer Center of Western Wisconsin', 'geoPoint': {'lat': 45.12302, 'lon': -92.53659}}, {'zip': '53066', 'city': 'Oconomowoc', 'state': 'Wisconsin', 'country': 'United States', 'facility': 'ProHealth Oconomowoc Memorial Hospital', 'geoPoint': {'lat': 43.11167, 'lon': -88.49927}}, {'zip': '53188', 'city': 'Waukesha', 'state': 'Wisconsin', 'country': 'United States', 'facility': 'ProHealth Waukesha Memorial Hospital', 'geoPoint': {'lat': 43.01168, 'lon': -88.23148}}, {'zip': '53188', 'city': 'Waukesha', 'state': 'Wisconsin', 'country': 'United States', 'facility': 'UW Cancer Center at ProHealth Care', 'geoPoint': {'lat': 43.01168, 'lon': -88.23148}}, {'zip': '00927', 'city': 'San Juan', 'country': 'Puerto Rico', 'facility': 'Centro Comprensivo de Cancer de UPR', 'geoPoint': {'lat': 18.46633, 'lon': -66.10572}}], 'overallOfficials': [{'name': 'Shaji K Kumar', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'ECOG-ACRIN Cancer Research Group'}]}, 'ipdSharingStatementModule': {'url': 'https://grants.nih.gov/policy/sharing.htm', 'ipdSharing': 'YES', 'description': 'NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page.'}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'National Cancer Institute (NCI)', 'class': 'NIH'}, 'responsibleParty': {'type': 'SPONSOR'}}}}